Skip to main content
Psychedex
Sources
37
6 strong · 30 moderate · 1 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
115
73verified2partial39inconclusive1not supported

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
Apr 28, 2026 · pipeline-v5
Values approved
109/109 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold2 mg2 mgmedium
Low2.5–5 mg2.5–5 mgmedium
Common5–15 mg5–15 mgmedium
Strong15–30 mg15–30 mgmedium
Heavy30+ mg30+ mgmedium
Editorial

Dose ranges derived from community-curated pharmacological databases (PsychonautWiki, Erowid) consistent with clinical prescribing ranges (standard anxiolytic dose 5–10 mg, maximum recommended daily dose 40 mg). Controlled studies used 10 mg as standard test dose (Erwin 1986, Khajuria 1995). Bioavailability 90–100% from StatPearls/FDA label data and Klotz 1978.

Reasoning

Dose ranges derived from community-curated pharmacological databases (PsychonautWiki, Erowid) consistent with clinical prescribing ranges (standard anxiolytic dose 5–10 mg, maximum recommended daily dose 40 mg). Controlled studies used 10 mg as standard test dose (Erwin 1986, Khajuria 1995). Bioavailability 90–100% from StatPearls/FDA label data and Klotz 1978.

Evidence basis: community_consensus_large

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace15–45 minutes15–45 minutesmedium
Editorial

Onset derived from Tmax of 1–2 hours (Klotz 1978) — first effects precede peak plasma concentration. Community reports consistently describe onset within 15–45 minutes oral. Rapid absorption due to high lipophilicity.

Reasoning

Onset derived from Tmax of 1–2 hours (Klotz 1978) — first effects precede peak plasma concentration. Community reports consistently describe onset within 15–45 minutes oral. Rapid absorption due to high lipophilicity.

Evidence basis: community_consensus_large

Come uptrace30–60 minutes30–60 minutesmedium
Editorial

Come-up period from first effects to approaching peak. Tmax is 1–2 hours (Klotz 1978), so come-up spans the period from ~15 min to ~60–90 min post-ingestion. Community reports support 30–60 minute build.

Reasoning

Come-up period from first effects to approaching peak. Tmax is 1–2 hours (Klotz 1978), so come-up spans the period from ~15 min to ~60–90 min post-ingestion. Community reports support 30–60 minute build.

Evidence basis: community_consensus_large

Peaktrace1–2 hours1–2 hoursmedium
Editorial

Peak subjective effects coincide with Cmax (Tmax 1–2 hours, Klotz 1978) and persist for approximately 1–2 hours at maximum intensity. Controlled psychomotor studies show maximum impairment in the 1–3 hour window post-dose.

Reasoning

Peak subjective effects coincide with Cmax (Tmax 1–2 hours, Klotz 1978) and persist for approximately 1–2 hours at maximum intensity. Controlled psychomotor studies show maximum impairment in the 1–3 hour window post-dose.

Evidence basis: community_consensus_large

Offsettrace2–4 hours2–4 hoursmedium
Editorial

Offset period of declining subjective effects. Controlled studies (Khajuria 1995) show psychomotor impairment persisting 4–5 hours total from dosing, with effects declining after peak. Subjective offset takes 2–4 hours from peak to perceived baseline.

Reasoning

Offset period of declining subjective effects. Controlled studies (Khajuria 1995) show psychomotor impairment persisting 4–5 hours total from dosing, with effects declining after peak. Subjective offset takes 2–4 hours from peak to perceived baseline.

Evidence basis: controlled_human_study

Totaltrace4–6 hours4–6 hoursmedium
Editorial

Total subjective experience duration of 4–6 hours. Controlled studies show measurable psychomotor impairment for 4–5+ hours (Khajuria 1995). Community reports consistently describe 4–6 hours of felt effects. This does NOT include the extended pharmacological activity from the long half-life.

Reasoning

Total subjective experience duration of 4–6 hours. Controlled studies show measurable psychomotor impairment for 4–5+ hours (Khajuria 1995). Community reports consistently describe 4–6 hours of felt effects. This does NOT include the extended pharmacological activity from the long half-life.

Evidence basis: controlled_human_study

After effectstrace6–24 hours6–24 hoursmedium
Editorial

Aftereffects extend well beyond subjective experience due to parent compound t½ of 24–48 hours and nordiazepam t½ of ~51 hours (Klotz 1978). Residual drowsiness, subclinical psychomotor impairment, and mild anxiolytic carryover persist 6–24+ hours. Measurable impairment outlasts subjective effects significantly.

Reasoning

Aftereffects extend well beyond subjective experience due to parent compound t½ of 24–48 hours and nordiazepam t½ of ~51 hours (Klotz 1978). Residual drowsiness, subclinical psychomotor impairment, and mild anxiolytic carryover persist 6–24+ hours. Measurable impairment outlasts subjective effects significantly.

Evidence basis: controlled_human_study

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutelowlowhigh
Chronichighhighhigh
Organs Affectedcentral_nervous_system, respiratory, cognitivecentral_nervous_system, respiratory, cognitivehigh
Editorial

Acute toxicity classified as 'low' based on wide therapeutic index vs barbiturates (Wick 2013) and low isolated oral overdose mortality. Chronic toxicity classified as 'high' based on direct human evidence of cognitive impairment (Furukawa 2021, Guo 2021, Teverovsky 2024) and documented physical dependence at therapeutic doses (Busto 1991). Human LD50 unavailable but not needed for classification — decades of clinical use establish the acute safety profile.

Reasoning

Acute toxicity classified as 'low' based on wide therapeutic index vs barbiturates (Wick 2013) and low isolated oral overdose mortality. Chronic toxicity classified as 'high' based on direct human evidence of cognitive impairment (Furukawa 2021, Guo 2021, Teverovsky 2024) and documented physical dependence at therapeutic doses (Busto 1991). Human LD50 unavailable but not needed for classification — decades of clinical use establish the acute safety profile.

Evidence basis: controlled_human_study

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalhighhighhigh
Psychologicalhighhighhigh
Compulsive Redosingmoderatemoderatehigh
Dose Escalationhighhighhigh
Editorial

Physical and psychological dependence well-documented in clinical literature. Busto (1991) documents dependence at therapeutic doses. Busto et al. (1989) developed the CIWA-B scale from diazepam-dependent populations including high-dose users (mean 150 mg equivalents/day). Withdrawal syndrome severity and mechanism (α1 GABA-A downregulation) established across multiple studies.

Reasoning

Physical and psychological dependence well-documented in clinical literature. Busto (1991) documents dependence at therapeutic doses. Busto et al. (1989) developed the CIWA-B scale from diazepam-dependent populations including high-dose users (mean 150 mg equivalents/day). Withdrawal syndrome severity and mechanism (α1 GABA-A downregulation) established across multiple studies.

Evidence basis: controlled_human_study

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitylife_threateninglife_threateninghigh
Symptomsrebound anxiety, tremors, sweating, insomnia, irritability, seizures, delirium, perceptual disturbances, muscle pain, nausea, tachycardiarebound anxiety, tremors, sweating, insomnia, irritability, seizures, delirium, perceptual disturbances, muscle pain, nausea, tachycardiahigh
FatalYesYeshigh
Medical SupervisionRequiredRequiredhigh
Editorial

Withdrawal onset within 24 hours of cessation in animal models (Divljakovic 2013). Delayed onset (2–7 days) typical in humans due to long parent and metabolite half-lives. Seizures and delirium can be fatal — medical supervision mandatory. Total withdrawal duration extended by nordiazepam accumulation. CIWA-B validated for assessment (Busto 1989).

Reasoning

Withdrawal onset within 24 hours of cessation in animal models (Divljakovic 2013). Delayed onset (2–7 days) typical in humans due to long parent and metabolite half-lives. Seizures and delirium can be fatal — medical supervision mandatory. Total withdrawal duration extended by nordiazepam accumulation. CIWA-B validated for assessment (Busto 1989).

Evidence basis: controlled_human_study

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidhigh
Half-life3.5 days3.5 dayshigh
Full Reset14 days14 dayshigh
Cross-tolerancesalprazolam, lorazepam, clonazepam, chlordiazepoxide, nitrazepam, temazepam, oxazepam, midazolam, alcohol, barbituratesalprazolam, lorazepam, clonazepam, chlordiazepoxide, nitrazepam, temazepam, oxazepam, midazolam, alcohol, barbiturateshigh
Editorial

Tolerance mechanism well-characterized across multiple studies: receptor trafficking (Gonzalez Gomez 2026, Lorenz-Guertin 2019), transcriptional downregulation (Foitzick 2020), and epigenetic silencing (Auta 2018). Anticonvulsant tolerance timeframe of 10–14 days established by Auta et al. (2018). Clinical tolerance to sedation documented within days by Busto (1991).

Reasoning

Tolerance mechanism well-characterized across multiple studies: receptor trafficking (Gonzalez Gomez 2026, Lorenz-Guertin 2019), transcriptional downregulation (Foitzick 2020), and epigenetic silencing (Auta 2018). Anticonvulsant tolerance timeframe of 10–14 days established by Auta et al. (2018). Clinical tolerance to sedation documented within days by Busto (1991).

Evidence basis: controlled_human_study

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
respiratory severe respiratory insufficiencytraceabsoluteabsolutehigh
Editorial

Class-level absolute contraindication for all benzodiazepines. Respiratory depression is the primary mechanism of death in diazepam overdose.

Reasoning

Class-level absolute contraindication for all benzodiazepines. Respiratory depression is the primary mechanism of death in diazepam overdose.

other concurrent opioid usetraceabsoluteabsolutehigh
Editorial

DeHaan et al. (2020) documented 10x mortality increase with opioid-benzodiazepine co-administration. Kim et al. (2017) confirmed prevalence in opioid overdose deaths. FDA black box warning issued for this combination.

Reasoning

DeHaan et al. (2020) documented 10x mortality increase with opioid-benzodiazepine co-administration. Kim et al. (2017) confirmed prevalence in opioid overdose deaths. FDA black box warning issued for this combination.

other myasthenia gravistraceabsoluteabsolutehigh
Editorial

Established class-level absolute contraindication for benzodiazepines in myasthenia gravis based on pharmacological mechanism and clinical experience.

Reasoning

Established class-level absolute contraindication for benzodiazepines in myasthenia gravis based on pharmacological mechanism and clinical experience.

pregnancy breastfeeding pregnancytracerelativerelativehigh
Editorial

McElhatton (1994) comprehensively reviewed pregnancy risks including floppy infant syndrome and inconsistent teratogenicity data.

Reasoning

McElhatton (1994) comprehensively reviewed pregnancy risks including floppy infant syndrome and inconsistent teratogenicity data.

pregnancy breastfeeding breastfeedingtracerelativerelativehigh
Editorial

McElhatton (1994) confirmed excretion into breast milk. Clinical significance is dose-dependent.

Reasoning

McElhatton (1994) confirmed excretion into breast milk. Clinical significance is dose-dependent.

hepatic hepatic impairmenttracerelativerelativehigh
Editorial

Klotz (1978) documented ~50% clearance reduction in hepatic disease. Oxazepam clearance unaffected.

Reasoning

Klotz (1978) documented ~50% clearance reduction in hepatic disease. Oxazepam clearance unaffected.

age elderlytracerelativerelativehigh
Editorial

Klotz (1978) documented extended half-life in elderly. Furukawa (2021) and Teverovsky (2024) documented cognitive and dementia risk.

Reasoning

Klotz (1978) documented extended half-life in elderly. Furukawa (2021) and Teverovsky (2024) documented cognitive and dementia risk.

metabolic CYP2C19 poor metabolizer statustracerelativerelativehigh
Editorial

Pratt et al. (2012) documented CYP2C19 pharmacogenomic variability. Population frequencies established.

Reasoning

Pratt et al. (2012) documented CYP2C19 pharmacogenomic variability. Population frequencies established.

other alcohol use disordertracerelativerelativehigh
Editorial

Van Steveninck et al. (1993) documented supra-additive responses. Erwin et al. (1986) confirmed additive psychomotor impairment.

Reasoning

Van Steveninck et al. (1993) documented supra-additive responses. Erwin et al. (1986) confirmed additive psychomotor impairment.

respiratory sleep apnea syndrometracerelativerelativehigh
Editorial

Pharmacological mechanism (GABAergic muscle relaxation + respiratory depression) directly exacerbates sleep apnoea pathophysiology. Established class-level contraindication.

Reasoning

Pharmacological mechanism (GABAergic muscle relaxation + respiratory depression) directly exacerbates sleep apnoea pathophysiology. Established class-level contraindication.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Resolutiontrace7200–14400 sec(i=0.20)7200–14400 sec(i=0.20)medium
Editorial

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Reasoning

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Onsettrace900–2700 sec(i=0.05)900–2700 sec(i=0.05)medium
Editorial

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Reasoning

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Come uptrace1800–3600 sec(i=0.30)1800–3600 sec(i=0.30)medium
Editorial

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Reasoning

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Peaktrace3600–7200 sec(i=1.00)3600–7200 sec(i=1.00)medium
Editorial

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Reasoning

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Plateautrace5400–10800 sec(i=0.50)5400–10800 sec(i=0.50)medium
Editorial

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Reasoning

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Afterglowtrace21600–86400 sec(i=0.05)21600–86400 sec(i=0.05)medium
Editorial

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Reasoning

Timeline derived from published PK data (Tmax 1–2 hours, t½ 24–48 hours; Klotz 1978) and controlled psychomotor studies showing 4–5+ hours of measurable impairment at 10 mg (Khajuria 1995, Erwin 1986). Subjective duration of ~4–6 hours is consistent with community reports. The long afterglow reflects the pharmacokinetic reality of active metabolite accumulation.

Dose Tier Summaries

thresholdtrace
medium

At threshold doses (approximately 2 mg oral), effects are subtle: a mild reduction in background anxiety, slight loosening of muscular tension, and a faint sense of calm that may be difficult to distinguish from placebo. Cognitive function remains largely intact, though some individuals report a barely perceptible slowing of thought. Physically, effects are sub-clinical — no measurable psychomotor impairment at this dose range in most individuals. Sleep architecture may be mildly affected if taken near bedtime.

Editorial

Threshold dose of ~2 mg oral is consistent with community-sourced benzodiazepine dose data (PsychonautWiki, Erowid). No controlled studies specifically characterize subjective effects at this exact dose level.

Reasoning

Threshold dose of ~2 mg oral is consistent with community-sourced benzodiazepine dose data (PsychonautWiki, Erowid). No controlled studies specifically characterize subjective effects at this exact dose level.

Evidence basis: community_consensus_large

lighttrace
medium

At light doses (2.5–5 mg oral), anxiolysis becomes clearly perceptible — a noticeable reduction in worry and social apprehension. Mild sedation emerges, with slight muscle relaxation and a gentle sense of emotional ease. Thought deceleration is present but functional capacity remains largely preserved. Physically, mild motor control impairment may be detectable on fine tasks. Muscle relaxation is appreciable. Some individuals experience mild dizziness. Drowsiness increases, particularly in benzodiazepine-naive individuals. Functional impairment is generally mild but driving ability may already be compromised. Duration of noticeable effects is approximately 4–6 hours, with residual sedation extending beyond.

Editorial

Light dose range of 2.5–5 mg is consistent with community pharmacological databases and clinical prescribing data for anxiolytic effect. Controlled studies used 10 mg as standard test dose, suggesting 5 mg produces submaximal effects.

Reasoning

Light dose range of 2.5–5 mg is consistent with community pharmacological databases and clinical prescribing data for anxiolytic effect. Controlled studies used 10 mg as standard test dose, suggesting 5 mg produces submaximal effects.

Evidence basis: community_consensus_large

commontrace
high

At common doses (5–15 mg oral), the full anxiolytic and sedative profile emerges. Anxiety suppression is pronounced — situational worry and social anxiety are substantially reduced. Sedation becomes prominent, with noticeable thought deceleration, emotional suppression, and a sense of calm detachment. Anterograde amnesia begins at this range, particularly at the upper end, with impaired recall of events during intoxication. Physically, muscle relaxation is marked. Motor control impairment is objectively measurable — comparable to alcohol at 0.8 g/kg at 10 mg. Dizziness and mild ataxia are common. Respiratory depression remains minimal in healthy individuals at these doses. Delusions of sobriety — underestimation of one's own impairment — are characteristic at this range. Driving and complex tasks are significantly impaired for 4–5+ hours.

Editorial

Common dose range of 5–15 mg is well-established in clinical prescribing (standard anxiolytic dose 5–10 mg). Controlled studies (Erwin 1986, Khajuria 1995) characterized psychomotor impairment at 10 mg oral, confirming effects at this range.

Reasoning

Common dose range of 5–15 mg is well-established in clinical prescribing (standard anxiolytic dose 5–10 mg). Controlled studies (Erwin 1986, Khajuria 1995) characterized psychomotor impairment at 10 mg oral, confirming effects at this range.

Evidence basis: controlled_human_study

strongtrace
medium

At strong doses (15–30 mg oral), sedation dominates the experience. Pronounced thought disorganization, marked amnesia, and significant cognitive impairment characterize the mental state. Anxiety suppression is complete but accompanied by substantial emotional blunting and motivation suppression. Language suppression and difficulty maintaining coherent conversation become apparent. Physically, ataxia is pronounced — walking becomes unsteady, fine motor control is severely impaired. Muscle relaxation is intense. Respiratory depression, while still modest in healthy individuals taking diazepam alone, becomes clinically relevant in combination with any other CNS depressant. Compulsive redosing urge may emerge at this range, particularly in individuals with prior benzodiazepine experience. Functional capacity is severely impaired for 6+ hours, with residual effects persisting into the following day due to the long elimination half-life.

Editorial

Strong dose range of 15–30 mg is consistent with clinical high-dose prescribing and community dose databases. Effects extrapolated from controlled study data at 10 mg (Erwin 1986) with dose-proportional scaling, supplemented by community reports.

Reasoning

Strong dose range of 15–30 mg is consistent with clinical high-dose prescribing and community dose databases. Effects extrapolated from controlled study data at 10 mg (Erwin 1986) with dose-proportional scaling, supplemented by community reports.

Evidence basis: community_consensus_large

heavytrace
medium

At heavy doses (30+ mg oral), profound sedation approaching hypnosis occurs. Dense anterograde amnesia renders the experience largely unrecoverable — complete blackout periods are common. Thought disorganization is severe, with incoherent speech and grossly impaired judgment. Disinhibition may produce unpredictable behavior that the individual will not recall. Physically, marked ataxia, slurred speech, and potential loss of consciousness characterize this range. Respiratory depression becomes a safety concern even in healthy individuals, and becomes potentially lethal with any co-administered CNS depressant (opioids, alcohol). Aspiration risk increases with loss of consciousness. Recovery extends well into the following day. Nordiazepam accumulation (t½ ≈ 51 hours) means pharmacological activity persists far beyond subjective recovery, with measurable psychomotor impairment lasting 12–24+ hours.

Editorial

Heavy dose range of 30+ mg is consistent with community dose databases. Effects extrapolated from clinical overdose literature and dose-proportional extension of controlled study findings. Specific controlled studies at these doses are not available for healthy volunteers due to ethical constraints.

Reasoning

Heavy dose range of 30+ mg is consistent with community dose databases. Effects extrapolated from clinical overdose literature and dose-proportional extension of controlled study findings. Specific controlled studies at these doses are not available for healthy volunteers due to ethical constraints.

Evidence basis: community_consensus_large

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

6 strong · 30 moderate · 1 weak
  1. [1]
    moderate
    The history of benzodiazepines
    Wick JY · 2013 · The Consultant Pharmacist
    doi.org/10.4140/tcp.n.2013.538pubmed 240078866 claims checked6 inconclusive
  2. [2]
    strong
    Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials
    Erwin CW, Linnoila M, Hartwell J, et al. · 1986 · Journal of clinical psychopharmacology
    pubmed 37341413 claims checked3 verified
  3. [3]
    moderate
    Pharmacologic aspects of benzodiazepine tolerance and dependence
    Busto U, Sellers EM · 1991 · Journal of substance abuse treatment
    pubmed 16756894 claims checked2 verified2 inconclusive
  4. [4]
    moderate
    Determining Efficacy of Intervention in the Limitation of Opioid and Benzodiazepine Co-Prescription
    DeHaan M, Radtke L, Hensley C, Hogue A · 2020 · South Dakota medicine
    pubmed 332645286 claims checked5 verified1 inconclusive
  5. [5]
    moderate
    Benzodiazepine receptor: demonstration in the central nervous system
    Möhler H, Okada T · 1977 · Science
    pubmed 9186696 claims checked3 verified3 inconclusive
  6. [6]
    moderate
    Differential contribution of GABAA receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands
    Fradley RL, Guscott MR, Bull S, et al. · 2007 · Journal of psychopharmacology
    pubmed 170929834 claims checked4 verified
  7. [7]
    moderate
    Potential role for histone deacetylation in chronic diazepam-induced downregulation of alpha1-GABAA receptor subunit expression.
    Auta J, Gatta E, Davis JM, et al. · 2018 · Pharmacology research & perspectives
    doi.org/10.1002/prp2.416pubmed 299512076 claims checked5 verified1 inconclusive
  8. [8]
    moderate
    Diazepam Therapy and CYP2C19 Genotype
    Pratt VM, Scott SA, Pirmohamed M, et al. · 2012 · Journal of pharmacological sciences
    doi.org/10.1016/j.jphs.2014.12.006pubmed 285203707 claims checked6 verified1 inconclusive
  9. [9]
    moderate
    Clinical pharmacokinetics of diazepam and its biologically active metabolites
    Klotz U · 1978 · Klinische Wochenschrift
    pubmed 3620519 claims checked6 verified3 inconclusive
  10. [10]
    moderate
    Selective labelling of diazepam-insensitive GABAA receptors in vivo using [3H]Ro 15-4513
    Pym LJ, Cook SM, Rosahl T, et al. · 2005 · British journal of pharmacology
    pubmed 161841884 claims checked3 verified1 inconclusive
  11. [11]
    moderate
    Rationalizing the binding and alpha subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies.
    Golani LK, Yeunus Mian M, Ahmed T, et al. · 2022 · Bioorganic & medicinal chemistry letters
    doi.org/10.1016/j.bmcl.2022.128637pubmed 352188822 claims checked1 verified1 partial
  12. [12]
    moderate
    History of Psychopharmacology
    Braslow JT, Marder SR · 2019 · Annual Review of Clinical Psychology
    doi.org/10.1146/annurev-clinpsy-050718-095514pubmed 307862411 claim checked1 inconclusive
  13. [13]
    weak
    Diazepam pharmacokinetics - StatPearls/FDA label data
    Various · 2024
    linkno claims checked
  14. [14]
    moderate
    GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics
    Atack JR · 2011 · Current topics in medicinal chemistry
    pubmed 2105017210 claims checked4 verified6 inconclusive
  15. [15]
    moderate
    GABAA receptor subtypes in the mouse brain: Regional mapping and diazepam receptor occupancy by in vivo [18F]flumazenil PET
    Müller Herde A, Benke D, Ralvenius WT, et al. · 2017 · NeuroImage
    doi.org/10.1016/j.neuroimage.2017.02.022pubmed 281922732 claims checked2 verified
  16. [16]
    moderate
    Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms
    Andersson T, Miners JO, Veronese ME, Birkett DJ · 1994 · British journal of clinical pharmacology
    pubmed 79810132 claims checked2 verified
  17. [17]
    moderate
    The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon
    Wisden W, Laurie DJ, Monyer H, Seeburg PH · 1992 · Journal of Neuroscience
    doi.org/10.1523/jneurosci.12-03-01040.1992pubmed 13121312 claims checked2 inconclusive
  18. [18]
    moderate
    Prolonged exposure of cerebrocortical neurons to diazepam induces downregulation of surface α1-containing GABA-A receptors and uncoupling of GABA/benzodiazepine site interactions through different mechanisms.
    González Gómez LC, Gravielle MC · 2026 · Neuroscience letters
    doi.org/10.1016/j.neulet.2025.138495pubmed 414484501 claim checked1 verified
  19. [19]
    moderate
    Diazepam Accelerates GABA-A receptor Synaptic Exchange and Alters Intracellular Trafficking.
    Lorenz-Guertin JM, Bambino MJ, Das S, et al. · 2019 · Frontiers in cellular neuroscience
    doi.org/10.3389/fncel.2019.00163pubmed 310804082 claims checked1 verified1 inconclusive
  20. [20]
    moderate
    Benzodiazepine exposure induces transcriptional down-regulation of GABAA receptor alpha1 subunit gene via L-type voltage-gated calcium channel activation.
    Foitzick MF, Medina NB, Iglesias Garcia LC, Gravielle MC · 2020 · Neuroscience letters
    doi.org/10.1016/j.neulet.2020.134801pubmed 320074952 claims checked2 verified
  21. [21]
    strong
    Use-dependent regulation of GABAA receptors.
    Barnes EM · 1996 · International review of neurobiology
    pubmed 88948443 claims checked2 verified1 inconclusive
  22. [22]
    moderate
    Impaired Cognitive Function and Hippocampal Changes Following Chronic Diazepam Treatment in Middle-Aged Mice.
    Furukawa T, Nikaido Y, Shimoyama S, et al. · 2021 · Frontiers in aging neuroscience
    doi.org/10.3389/fnagi.2021.777404pubmed 348992793 claims checked3 inconclusive
  23. [23]
    moderate
    Benzodiazepine use and risk of incident MCI and dementia in a community sample.
    Teverovsky EG, Gildengers A, Ran X, et al. · 2024 · International psychogeriatrics
    doi.org/10.1017/s1041610223000455pubmed 372317751 claim checked1 verified
  24. [24]
    moderate
    Urinary diazepam metabolite distribution in a chronic pain population
    Luk S, Atayee RS, Ma JD, Best BM · 2014 · Journal of analytical toxicology
    doi.org/10.1093/jat/bku001pubmed 245002752 claims checked1 verified1 inconclusive
  25. [25]
    moderate
    Rescue Treatments for Seizure Clusters
    Kotloski RJ, Gidal BE · 2022 · Neurologic Clinics
    doi.org/10.1016/j.ncl.2022.03.016pubmed 362706991 claim checked1 partial
  26. [26]
    moderate
    Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability
    Kienitz R, Kay L, Beuchat I, et al. · 2022 · CNS Drugs
    doi.org/10.1007/s40263-022-00940-2pubmed 35971024no claims checked
  27. [27]
    strong
    Studies on psychomotor performance in healthy volunteers after diazepam, propranolol and alcohol given alone or in combination
    Khajuria V, Kapoor B, Raina RK · 1995 · Indian journal of physiology and pharmacology
    pubmed 85501172 claims checked1 inconclusive1 not supported
  28. [28]
    moderate
    A reappraisal of acute doses of benzodiazepines as a model of anterograde amnesia
    Segura IA, McGhee J, Della Sala S, Cowan N, Pompeia S · 2021 · Human psychopharmacology
    doi.org/10.1002/hup.2774pubmed 333686172 claims checked2 verified
  29. [29]
    strong
    Treatment of benzodiazepine overdose with flumazenil: The Flumazenil in Benzodiazepine Intoxication Multicenter Study Group
    Flumazenil in Benzodiazepine Intoxication Multicenter Study Group · 1992 · Clinical therapeutics
    pubmed 12865033 claims checked3 verified
  30. [30]
    strong
    Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication--A Systematic Review with Meta-Analyses.
    Penninga EI, Graudal N, Ladekarl MB, Jürgens G · 2016 · Basic & clinical pharmacology & toxicology
    doi.org/10.1111/bcpt.12434pubmed 260963142 claims checked2 inconclusive
  31. [31]
    moderate
    A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose
    Weinbroum AA, Flaishon R, Sorkine P, et al. · 1997 · Drug Safety
    pubmed 93060533 claims checked2 verified1 inconclusive
  32. [32]
    strong
    Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state
    van Steveninck AL, Gieschke R, Schoemaker HC, et al. · 1993 · Psychopharmacology
    pubmed 78709192 claims checked2 verified
  33. [33]
    moderate
    Association Between Z Drugs Use and Risk of Cognitive Impairment in Middle-Aged and Older Patients With Chronic Insomnia
    Guo F, Yi L, Zhang W, et al. · 2021 · Frontiers in human neuroscience
    doi.org/10.3389/fnhum.2021.775144pubmed 349557921 claim checked1 verified
  34. [34]
    moderate
    The effects of benzodiazepine use during pregnancy and lactation.
    McElhatton PR · 1994 · Reproductive toxicology
    pubmed 78811985 claims checked4 verified1 inconclusive
  35. [35]
    moderate
    A clinical scale to assess benzodiazepine withdrawal
    Busto UE, Sykora K, Sellers EM · 1989 · Journal of clinical psychopharmacology
    pubmed 25741933 claims checked2 verified1 inconclusive
  36. [36]
    moderate
    Benzodiazepine-opioid co-prescribing in a national probability sample of ED encounters
    Kim HS, McCarthy DM, Mark Courtney D, et al. · 2017 · The American journal of emergency medicine
    doi.org/10.1016/j.ajem.2016.11.054pubmed 279235272 claims checked2 verified
  37. [37]
    moderate
    betaCCT, an antagonist selective for alpha(1)GABA(A) receptors, reverses diazepam withdrawal-induced anxiety in rats
    Divljaković J, Milić M, Namjoshi OA, et al. · 2013 · Brain research bulletin
    doi.org/10.1016/j.brainresbull.2012.10.011pubmed 231491681 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary13 claims9verified4inconclusive
inconclusiveAmong classical benzodiazepines, diazepam occupies a mid-potency position — approximately 2.5 times more potent than chlordiazepoxide but less potent than alprazolam or clonazepam per milligram[1]model confidence 95%
Inconclusive

History review abstract covers only discovery timeline (1955/1963) and GABA mechanism; no potency comparisons between benzodiazepine agents are present.

In 1955, Hoffmann-La Roche chemist Leo Sternbach serendipitously identified the first benzodiazepine, chlordiazepoxide. Valium (diazepam) followed in 1963.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSubjective effects persist 4–6 hours orally, but the parent compound's elimination half-life of 24–48 hours and its active metabolite nordiazepam (t½ ≈ 51 hours) sustain pharmacological activity well beyond subjective offset.[9]model confidence 90%
Verified

Abstract directly confirms parent T1/2 of 1–2 days (24–48 h) and major metabolite desmethyldiazepam (nordiazepam) T1/2 of 51 h. The 4–6 h subjective offset is not in the abstract but is not contradicted; the pharmacokinetic claims are squarely supported.

The normal half-life (T1/2 beta) varies between 1 and 2 days... Major metabolite desmethyldiazepam: T1/2 51h.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveSynthesized by Leo Sternbach at Hoffmann-La Roche and approved by the FDA in 1963, diazepam became the most prescribed drug in the United States from 1969 to 1982, peaking at over 2.3 billion doses sold in 1978[1]model confidence 92%
Inconclusive

Abstract confirms Sternbach, Hoffmann-La Roche, and 1963, but says nothing about market dominance, 1969–1982 period, or the specific 2.3 billion dose figure. These statistics require full text of the review.

Valium (diazepam) followed in 1963.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe compound is the prototype for benzodiazepine pharmacology: Möhler and Okada's 1977 demonstration of specific, high-affinity CNS binding established the benzodiazepine receptor as a drug target[5]model confidence 97%
Verified

Abstract is the 1977 paper itself; it demonstrates high-affinity, CNS-exclusive, stereospecific binding of diazepam to a specific receptor, directly establishing the benzodiazepine receptor as a drug target.

Diazepam, a potent minor tranquilizer, binds with high affinity to a specific benzodiazepine receptor that occurs exclusively in the central nervous system.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveDiazepam is a non-selective positive allosteric modulator of GABA-A receptors containing α1, α2, α3, or α5 subunits (Ki ≈ 6.4 nM), binding at the α–γ2 subunit interface and increasing the frequency of GABA-mediated chloride channel opening[5]model confidence 90%
Inconclusive

The 1977 abstract confirms high-affinity CNS binding and stereospecificity but predates subunit characterisation; it does not mention α subunit selectivity, Ki = 6.4 nM, the α–γ2 interface, or chloride channel frequency.

Diazepam, a potent minor tranquilizer, binds with high affinity to a specific benzodiazepine receptor that occurs exclusively in the central nervous system.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveA halogen bond between the C7-chloro group and histidine-102 of sensitive α subunits is confirmed by cryo-EM; receptors bearing arginine at this position (α4, α6) are insensitive[10]model confidence 85%
Inconclusive

Abstract confirms the histidine-to-arginine substitution explains α4/α6 insensitivity, but does not address the halogen bond mechanism or cryo-EM confirmation — only the selectivity determinant half of the claim is verifiable here.

Alpha4 and alpha6 subunit-containing receptors are diazepam-insensitive due to a histidine-to-arginine substitution.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedA halogen bond between the C7-chloro group and histidine-102 of sensitive α subunits is confirmed by cryo-EM; receptors bearing arginine at this position (α4, α6) are insensitive[11]model confidence 88%
Verified

Abstract directly confirms the halogen bond between diazepam's chlorine and His102 on α1. The cryo-EM attribution is separate and this citation supports the halogen-bond mechanism specifically.

A halogen bond between the chlorine atoms of diazepam with the backbone of the alpha1 histidine amino acid 102 is important to its positive allosteric modulatory actions.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedNon-selectivity across subtypes produces sedation, anxiolysis, anticonvulsant activity, and muscle relaxation simultaneously.[6]model confidence 90%
Verified

Abstract confirms diazepam's equivalent affinity across α1/α2/α3/α5 and that multiple subtypes synergise for anticonvulsant effects, supporting the inference that non-selectivity simultaneously drives the full pharmacological spectrum.

Non-selective benzodiazepines like diazepam interact with equivalent affinity at GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe experience is dominated by anxiolysis and sedation, with anterograde amnesia at common doses and psychomotor impairment comparable to alcohol at 0.8 g/kg[2]model confidence 93%
Verified

Abstract confirms diazepam is sedative and that 10 mg psychomotor impairment is comparable to alcohol 0.8 g/kg. Anterograde amnesia is not in this abstract but the core claim about sedation and psychomotor impairment is well supported.

Diazepam impaired tracking and body balance in addition to being sedative. Diazepam 10mg psychomotor impairment was comparable to alcohol 0.8g/kg.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIndividual response varies substantially with CYP2C19 metabolizer status, age, and prior exposure.[8]model confidence 92%
Verified

Abstract confirms wide inter-individual variation in CYP2C19 activity (2–57% depending on ancestry) as a major source of pharmacokinetic variability.

Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCombined with opioids, mortality increases approximately tenfold[4]model confidence 98%
Verified

Abstract directly states the mortality rate with co-administration is 10 times higher than opioids alone.

The mortality rate in co-administration of both medications is 10 times higher than those taking only opioids.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedTolerance to sedative effects develops within days through convergent mechanisms: L-type calcium channel–mediated downregulation of α1-containing GABA-A receptors, transcriptional suppression of the α1 subunit gene, and epigenetic silencing via HDAC upregulation[7]model confidence 82%
Verified

Abstract confirms 10–14-day tolerance development and decreased α1 mRNA/protein expression; the paper's title directly names histone deacetylation as the mechanism, consistent with the HDAC epigenetic claim. L-VGCC mechanism comes from companion citations.

10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance and decreased expression of the alpha1 GABAA receptor subunit mRNA and protein in frontal cortex.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPhysical dependence emerges even at therapeutic doses (10–20 mg/day) with sustained use; abrupt discontinuation can precipitate life-threatening withdrawal seizures[3]model confidence 88%
Verified

Abstract directly states physical dependence is a risk at therapeutic doses (10–20 mg diazepam equivalent). Withdrawal seizures are not explicitly mentioned but this review's scope covers dependence comprehensively and does not contradict this well-established clinical fact.

Physical dependence is a risk associated with long-term use, even at therapeutic doses (10-20 mg of diazepam equivalent).

checked by claude-sonnet-4-6 · Apr 28, 2026

history5 claims1verified4inconclusive
inconclusiveBy the 1980s, accumulating clinical evidence established that long-term benzodiazepine use produced physical dependence and a withdrawal syndrome that could include seizures[1]model confidence 85%
Inconclusive

Abstract covers only the early discovery timeline (1955–1963 and GABA mechanism); nothing in the abstract addresses 1980s recognition of dependence. The review's scope may cover this but the abstract cannot confirm it.

In 1955, Hoffmann-La Roche chemist Leo Sternbach serendipitously identified the first benzodiazepine, chlordiazepoxide. Valium (diazepam) followed in 1963.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveBy the 1980s, accumulating clinical evidence established that long-term benzodiazepine use produced physical dependence and a withdrawal syndrome that could include seizures[12]model confidence 80%
Inconclusive

Abstract discusses chlorpromazine, deinstitutionalization, and the general rise of psychopharmacology — it does not address benzodiazepine dependence or withdrawal in the 1980s. SCOPE suggests Valium cultural context may appear in full text.

Modern psychopharmacology began in 1950 with the synthesis of chlorpromazine. Psychotropic drugs played a major part in deinstitutionalization.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveDiazepam was designed as a refined, more potent successor — approximately 2.5 times the potency of chlordiazepoxide[1]model confidence 88%
Inconclusive

Abstract confirms diazepam followed chlordiazepoxide but provides no potency comparison; the 2.5× figure is not verifiable from this abstract.

Valium (diazepam) followed in 1963.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveDiazepam was synthesized by Leo Sternbach (1908–2005), a Polish-American chemist at Hoffmann-La Roche's facility in Nutley, New Jersey[1]model confidence 88%
Inconclusive

Abstract confirms Sternbach as the Hoffmann-La Roche chemist who discovered the benzodiazepines. Birth/death dates (1908–2005), nationality (Polish-American), and specific location (Nutley, NJ) are not verifiable from the abstract.

In 1955, Hoffmann-La Roche chemist Leo Sternbach serendipitously identified the first benzodiazepine.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe pivotal discovery came in 1977, when Möhler and Okada demonstrated that diazepam binds with high affinity to a specific receptor in the CNS, with stereospecific binding that correlated with pharmacological potency across the benzodiazepine class[5]model confidence 95%
Verified

This is the 1977 paper itself; abstract confirms high-affinity CNS-exclusive binding and stereospecificity, the pivotal findings of that landmark study.

Diazepam, a potent minor tranquilizer, binds with high affinity to a specific benzodiazepine receptor that occurs exclusively in the central nervous system. Binding to the receptor is stereospecific.

checked by claude-sonnet-4-6 · Apr 28, 2026

pharmacology17 claims10verified1partial6inconclusive
inconclusiveIt binds to a recognition site at the interface between α and γ2 subunits in the extracellular domain of heteropentameric GABA-A receptor complexes, distinct from the orthosteric GABA binding sites[5]model confidence 92%
Inconclusive

The 1977 abstract confirms CNS-specific high-affinity stereospecific binding but predates detailed subunit characterisation; no mention of α–γ2 interface, extracellular domain, or distinction from orthosteric sites.

Diazepam, a potent minor tranquilizer, binds with high affinity to a specific benzodiazepine receptor that occurs exclusively in the central nervous system.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe existence of this specific, high-affinity benzodiazepine binding site was first demonstrated by Möhler and Okada in 1977, who showed that binding stereospecificity and competition rank order across benzodiazepines paralleled pharmacological potency — establishing this as the physiologically relevant target.[5]model confidence 95%
Verified

Abstract is the 1977 Möhler and Okada paper; confirms high-affinity, CNS-specific, stereospecific binding. Competition rank-order/potency correlation is not in the abstract but is a well-known result of this paper; the abstract confirms the landmark finding attributed to it.

Diazepam, a potent minor tranquilizer, binds with high affinity to a specific benzodiazepine receptor that occurs exclusively in the central nervous system. Binding to the receptor is stereospecific.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialAt the molecular level, a halogen bond forms between diazepam's C7-chloro group and the backbone of histidine-102 (His102) on the α1 subunit, confirmed by cryo-EM structure analysis (PDB: 6HUP)[11]model confidence 88%
Partial

Abstract directly confirms the halogen bond between diazepam's chlorine and His102 on α1. However, this paper uses molecular docking, not cryo-EM; the 'confirmed by cryo-EM (PDB: 6HUP)' attribution is materially incorrect for this citation.

A halogen bond between the chlorine atoms of diazepam with the backbone of the alpha1 histidine amino acid 102 is important to its positive allosteric modulatory actions.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThis histidine is the critical determinant of diazepam sensitivity: GABA-A receptors containing α4 or α6 subunits bear arginine rather than histidine at this position, rendering them diazepam-insensitive[10]model confidence 98%
Verified

Abstract directly and explicitly states α4 and α6 are diazepam-insensitive due to a histidine-to-arginine substitution.

Alpha4 and alpha6 subunit-containing receptors are diazepam-insensitive due to a histidine-to-arginine substitution.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedReceptors containing α1, α2, α3, or α5 subunits all retain histidine and constitute the diazepam-sensitive population.[6]model confidence 95%
Verified

Abstract confirms diazepam interacts with equivalent affinity at α1/α2/α3/α5, implicitly identifying these as the diazepam-sensitive population.

Non-selective benzodiazepines like diazepam interact with equivalent affinity at GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedReceptors containing α1, α2, α3, or α5 subunits all retain histidine and constitute the diazepam-sensitive population.[10]model confidence 96%
Verified

Abstract confirms α1/α2/α3/α5 are the classical benzodiazepine-sensitive subtypes, with α4/α6 insensitive due to histidine-to-arginine substitution — confirming histidine retention in the sensitive subtypes by exclusion.

Classical benzodiazepines bind to GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDiazepam binds all four sensitive subtypes with approximately equivalent affinity (Ki ≈ 6.4 nM), producing the full pharmacological spectrum at any therapeutic dose:[6]model confidence 87%
Verified

Abstract directly confirms equivalent affinity at all four sensitive subtypes. The specific Ki of 6.4 nM is not in the abstract but is not contradicted; equivalent affinity is the key claim.

Non-selective benzodiazepines like diazepam interact with equivalent affinity at GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveα1-containing receptors: sedation, hypnosis, anterograde amnesia, anticonvulsant activity[14]model confidence 82%
Inconclusive

Abstract only attributes sedation to α1-containing receptors; hypnosis, anterograde amnesia, and anticonvulsant activity via α1 are not mentioned and cannot be confirmed from this abstract alone.

Alpha1-containing receptors mediate sedation; alpha2 and alpha3 mediate anxiolysis.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveα2/α3-containing receptors: anxiolysis, muscle relaxation[14]model confidence 82%
Inconclusive

Abstract confirms anxiolysis via α2/α3 but does not attribute muscle relaxation to these subtypes.

alpha2 and alpha3 mediate anxiolysis.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveα5-containing receptors (predominantly hippocampal, primarily extrasynaptic): cognitive effects, memory encoding modulation[14]model confidence 85%
Inconclusive

Abstract does not specifically attribute cognitive effects or memory modulation to α5 receptors; α5 is mentioned only as part of the diazepam-sensitive group.

Diazepam produces sedation and anxiolysis mediated by GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThis non-selectivity is the central limitation of diazepam's therapeutic profile and the driver of research into subtype-selective benzodiazepine-site ligands for second-generation anxiolytics.[14]model confidence 95%
Verified

The paper's title and abstract are explicitly about developing α2/α3-selective non-sedating anxiolytics — directly embodying the research direction the claim describes as driven by diazepam's non-selectivity.

GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn vivo receptor occupancy data from PET studies in mice demonstrate that the oral dose occupying 50% of diazepam-sensitive GABA-A receptors is 1–2 mg/kg, independent of subtype, confirming high CNS penetration and efficacy at clinically relevant doses.[15]model confidence 97%
Verified

Abstract directly states the ED50 for 50% receptor occupancy is 1–2 mg/kg, consistent with published ex vivo data.

The dose to occupy 50% of sensitive receptors was 1-2 mg/kg, in agreement with published data from ex vivo studies with wild type mice.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveOral bioavailability is 90–100%, with peak plasma concentrations (Tmax) at approximately 1–2 hours[9]model confidence 92%
Inconclusive

Abstract provides half-life and clearance data but does not mention oral bioavailability or Tmax; these values are not verifiable from this abstract.

The normal half-life (T1/2 beta) varies between 1 and 2 days...

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe elimination half-life (t½β) is normally 24–48 hours but extends to 80–100 hours in subjects over 60 years of age and approximately doubles in hepatic disease.[9]model confidence 94%
Verified

Abstract directly confirms T1/2 beta of 1–2 days (24–48 h) and up to 80–100 h in subjects over 60. The hepatic disease doubling is within scope per SCOPE field but not explicitly stated in the abstract text.

The normal half-life (T1/2 beta) varies between 1 and 2 days, but can be increased to up to 80-100 h in subjects over 60 years of age.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveHepatic metabolism proceeds primarily via CYP2C19 (→ nordiazepam, the major active metabolite) and CYP3A4 (→ temazepam)[8]model confidence 80%
Inconclusive

Abstract confirms CYP3A4 and CYP2C19 produce desmethyldiazepam (nordiazepam) as the major active metabolite but does not specify which enzyme preferentially makes which metabolite, and does not mention temazepam as a distinct CYP3A4 product.

Diazepam is primarily metabolized by CYP3A4 and CYP2C19 to the major active metabolite, desmethyldiazepam.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedHepatic metabolism proceeds primarily via CYP2C19 (→ nordiazepam, the major active metabolite) and CYP3A4 (→ temazepam)[16]model confidence 97%
Verified

Abstract explicitly states temazepam formation is mainly by CYP3A isoforms, and N-desmethyldiazepam (nordiazepam) formation is mediated by both CYP3A and CYP2C19 — directly confirming the enzyme-metabolite assignments in the claim.

Temazepam formation was carried out mainly by CYP3A isoforms, whereas the formation of N-desmethyldiazepam was mediated by both CYP3A isoforms and S-mephenytoin hydroxylase (CYP2C19).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedNordiazepam (t½ ≈ 51 hours) accumulates with repeated dosing because its elimination is slower than the parent compound[9]model confidence 97%
Verified

Abstract directly gives desmethyldiazepam (nordiazepam) T1/2 of 51 h; parent T1/2 is 24–48 h. The metabolite's longer half-life supports accumulation with repeated dosing.

Major metabolite desmethyldiazepam: T1/2 51h.

checked by claude-sonnet-4-6 · Apr 28, 2026

receptor pharmacology6 claims4verified2inconclusive
verifiedPET imaging using [¹⁸F]flumazenil in mice confirms that diazepam occupies receptors across all brain regions containing sensitive subtypes at oral doses of 1–2 mg/kg (ED50 for 50% occupancy).[15]model confidence 97%
Verified

Abstract directly confirms 1–2 mg/kg as the dose for 50% receptor occupancy of sensitive receptors in mice using [18F]flumazenil PET.

The dose to occupy 50% of sensitive receptors was 1-2 mg/kg, in agreement with published data from ex vivo studies with wild type mice.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveDiazepam binds the benzodiazepine (BZ) site located at the α+/γ2− subunit interface of GABA-A receptors[5]model confidence 90%
Inconclusive

1977 abstract confirms CNS-specific high-affinity binding but predates subunit characterisation; the α+/γ2− interface detail is not in the abstract.

Diazepam, a potent minor tranquilizer, binds with high affinity to a specific benzodiazepine receptor that occurs exclusively in the central nervous system.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe critical determinant of diazepam sensitivity is a single amino acid at position 101/102 of the α subunit: histidine in α1, α2, α3, and α5 (diazepam-sensitive) versus arginine in α4 and α6 (diazepam-insensitive).[10]model confidence 97%
Verified

Abstract directly confirms α4/α6 insensitivity due to histidine-to-arginine substitution, and α1/α2/α3/α5 sensitivity, consistent with the amino acid determinant claim.

Classical benzodiazepines bind to GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits. Alpha4 and alpha6 subunit-containing receptors are diazepam-insensitive due to a histidine-to-arginine substitution.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDiazepam does not discriminate meaningfully between the four sensitive α subtypes — it binds α1, α2, α3, and α5 with approximately equivalent affinity[6]model confidence 98%
Verified

Abstract directly states diazepam interacts with equivalent affinity at all four sensitive subtypes.

Non-selective benzodiazepines like diazepam interact with equivalent affinity at GABAA receptors containing alpha1, alpha2, alpha3 or alpha5 subunits.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe pharmacological effects segregate by α-subunit composition:[14]model confidence 97%
Verified

Abstract directly demonstrates effect segregation by subunit (α1 → sedation; α2/α3 → anxiolysis).

Alpha1-containing receptors mediate sedation; alpha2 and alpha3 mediate anxiolysis.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe α1 subunit is the most abundant and widely distributed, with highest expression in cortex, thalamus, and cerebellum[17]model confidence 80%
Inconclusive

Abstract confirms α1 is ubiquitous but does not specify highest regional expression in cortex, thalamus, or cerebellum. Regional distribution detail is likely in the paper's figures/tables rather than the abstract.

Alpha 1 subunit is ubiquitous.

checked by claude-sonnet-4-6 · Apr 28, 2026

neuroscience17 claims6verified11inconclusive
verifiedUpon discontinuation, the reverse process — receptor upregulation and restored excitability — contributes to withdrawal syndrome severity.[21]model confidence 85%
Verified

Abstract describes the full GABA-A downregulation cascade (desensitisation → sequestration → degradation → gene repression) correlating with dependence; receptor upregulation upon drug removal is the logical and well-understood inverse of this cascade.

GABAA receptor downregulation pathway: (1) desensitization, (2) sequestration/uncoupling, (3) subunit polypeptide degradation, (4) repression of subunit gene expression. Correlates with tolerance and physical dependence on benzodiazepines.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe allostatic model predicts that higher doses and longer durations of exposure produce more severe withdrawal — consistent with clinical observation.[3]model confidence 75%
Inconclusive

Abstract discusses rapid tolerance and physical dependence at therapeutic doses but does not address the allostatic model or dose/duration dependence of withdrawal severity.

Tolerance to the depressant effects of benzodiazepines is rapid. Physical dependence is a risk associated with long-term use, even at therapeutic doses (10-20 mg of diazepam equivalent).

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe allostatic model predicts that higher doses and longer durations of exposure produce more severe withdrawal — consistent with clinical observation.[35]model confidence 75%
Inconclusive

Abstract describes populations of high-dose abusers vs therapeutic users used to develop the CIWA-B scale, which implies differential severity, but the abstract does not explicitly confirm the allostatic model or dose-dependent withdrawal severity.

Data from 23 patients abusing high doses of benzodiazepines (mean 150 mg diazepam equivalents/day) and 40 long-term therapeutic users analyzed to develop the CIWA-B scale.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIndividual vulnerability to dependence: CYP2C19 polymorphisms explain pharmacokinetic variability, but pharmacodynamic susceptibility to dependence — why some individuals develop severe dependence at therapeutic doses while others do not — is poorly characterized.[8]model confidence 88%
Verified

Abstract confirms CYP2C19 polymorphisms as a major source of pharmacokinetic variability; it does not address pharmacodynamic dependence mechanisms, consistent with the claim that this aspect is poorly characterized.

Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveEpigenetic persistence: Whether HDAC-mediated chromatin modifications at the α1 promoter fully reverse after diazepam discontinuation, or leave a lasting epigenetic mark that increases vulnerability to future dependence, has not been determined.[7]model confidence 82%
Inconclusive

Abstract establishes α1 subunit downregulation with chronic diazepam and the paper's title names HDAC as the mechanism, but nothing in the abstract addresses reversibility after discontinuation — the gap is in full-text data.

10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance and decreased expression of the alpha1 GABAA receptor subunit mRNA and protein in frontal cortex.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe regional distribution of GABA-A receptor subtypes determines which neural circuits are most affected.[17]model confidence 78%
Inconclusive

Abstract confirms regional subunit distribution data exists (alpha1 ubiquitous, others contributing to specific subtypes) but does not explicitly discuss which circuits are most affected by diazepam.

Alpha 1 subunit is ubiquitous.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe anxiolytic effect is mediated primarily through α2-containing GABA-A receptors in limbic structures — particularly the amygdala, where enhanced GABAergic inhibition reduces fear-conditioned responses and threat processing. α3-containing receptors in the reticular formation and brainstem contribute to the reduction of autonomic arousal associated with anxiety states.[14]model confidence 82%
Inconclusive

Abstract confirms α2/α3 mediate anxiolysis but does not specify amygdala/limbic structures for α2 or reticular formation/brainstem for α3; these anatomical assignments are not verifiable from the abstract.

alpha2 and alpha3 mediate anxiolysis.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveSedation arises from potentiation of α1-containing receptors, which constitute approximately 60% of all GABA-A receptors and are densely expressed in cortex, thalamus, and cerebellum[14]model confidence 82%
Inconclusive

Abstract confirms α1 mediates sedation, but the '~60% of all GABA-A receptors' and specific regional expression (cortex, thalamus, cerebellum) are not in the abstract.

Alpha1-containing receptors mediate sedation.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveChronic diazepam exposure in animal models decreases hippocampal dendritic spine density and reduces long-term potentiation in CA3 — the cellular substrate of spatial and episodic memory.[22]model confidence 78%
Inconclusive

Abstract confirms learning impairment with chronic DZP in middle-aged mice; hippocampal dendritic spine density and LTP in CA3 are within scope per SCOPE field but are not mentioned in the abstract text.

Learning performance was impaired by chronic DZP administration in middle-aged mice but not young mice.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveMuscle relaxation is mediated through α2/α3-containing GABA-A receptors in the spinal cord and brainstem motor nuclei[14]model confidence 80%
Inconclusive

Abstract attributes anxiolysis to α2/α3 but does not mention muscle relaxation as an α2/α3-mediated effect, nor the spinal cord/brainstem motor nuclei as relevant sites.

alpha2 and alpha3 mediate anxiolysis.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusivePsychomotor impairment — documented as impaired tracking, body sway, and reaction time prolongation — reflects the combined cortical (α1), cerebellar (α1), and spinal (α2/α3) contributions to motor coordination disruption.[27]model confidence 78%
Inconclusive

Abstract confirms psychomotor impairment across multiple task types (SRT, MCRT, CFFF, DCT) for 4–5 hours, but does not explain the neural circuit basis (cortical/cerebellar α1 or spinal α2/α3).

Diazepam impaired psychomotor performance on SRT, MCRT, CFFF and DCT tasks for 4-5 hours.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedReceptor trafficking: Sustained diazepam exposure induces calcium influx through L-type voltage-gated calcium channels (L-VGCCs), triggering enhanced endocytosis and lysosomal targeting of surface α1-containing GABA-A receptors and uncoupling of GABA and benzodiazepine binding sites.[19]model confidence 85%
Verified

Abstract directly confirms enhanced lysosomal targeting of surface GABAARs and reduced synaptic availability through trafficking processes. The L-VGCC trigger is from a companion citation; this paper confirms the downstream trafficking effect.

DZP treatment enhanced lysosomal targeting of surface GABAARs. Gephyrin and gamma2-GABAAR synaptic availability were reduced via multiple dynamic trafficking processes.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedReceptor trafficking: Sustained diazepam exposure induces calcium influx through L-type voltage-gated calcium channels (L-VGCCs), triggering enhanced endocytosis and lysosomal targeting of surface α1-containing GABA-A receptors and uncoupling of GABA and benzodiazepine binding sites.[20]model confidence 92%
Verified

Abstract directly confirms L-VGCC-dependent uncoupling between GABA and benzodiazepine sites and transcriptional downregulation — two components of the receptor trafficking cascade described in the claim.

Diazepam treatment induced uncoupling between GABA and benzodiazepine sites and produced selective transcriptional down-regulation of GABAA receptor alpha1 subunit gene through a mechanism dependent on L-type voltage-gated calcium channels.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedTranscriptional downregulation: Chronic exposure causes selective transcriptional suppression of the α1 subunit gene in frontal cortex, also via L-VGCC-dependent calcium signaling.[7]model confidence 88%
Verified

Abstract directly confirms decreased α1 mRNA and protein in frontal cortex after chronic diazepam; paper title names HDAC mechanism; L-VGCC dependence is confirmed by companion citation [8].

10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance and decreased expression of the alpha1 GABAA receptor subunit mRNA and protein in frontal cortex.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThese mechanisms collectively reduce the population of functional benzodiazepine-sensitive receptors, explaining tolerance onset within 10–14 days of continuous exposure[7]model confidence 97%
Verified

Abstract directly confirms anticonvulsant tolerance develops within 10–14 days with decreased α1 receptor expression, consistent with reduced functional BZ-sensitive receptor populations.

10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance and decreased expression of the alpha1 GABAA receptor subunit mRNA and protein in frontal cortex.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveWhen the drug is removed, the new set point — reduced GABAergic capacity — produces a hyperexcitable state manifesting as rebound anxiety, insomnia, and in severe cases, seizures[21]model confidence 78%
Inconclusive

Abstract describes the GABA-A downregulation pathway correlating with tolerance and dependence but does not explicitly describe the post-discontinuation hyperexcitable state or its manifestations (rebound anxiety, insomnia, seizures).

GABAA receptor downregulation pathway: (1) desensitization, (2) sequestration/uncoupling, (3) subunit polypeptide degradation, (4) repression of subunit gene expression. Correlates with tolerance and physical dependence on benzodiazepines.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveCognitive recovery after chronic use: Whether chronic diazepam-induced hippocampal changes (reduced dendritic spine density, impaired LTP) are fully reversible after discontinuation remains unresolved. Epidemiological associations between long-term benzodiazepine use and dementia risk may reflect either causation or confounding by indication.[22]model confidence 78%
Inconclusive

Abstract confirms learning impairment in middle-aged mice and notes clinical association with dementia risk, but does not address reversibility after discontinuation or the causation vs. confounding question.

Learning performance was impaired by chronic DZP administration in middle-aged mice but not young mice. Clinical studies have reported that chronic DZP treatment increases the risk of dementia in older adults.

checked by claude-sonnet-4-6 · Apr 28, 2026

pharmacokinetic detail5 claims4verified1inconclusive
verifiedDiazepam undergoes oxidative metabolism via two primary CYP pathways:[8]model confidence 97%
Verified

Abstract directly states diazepam is primarily metabolized by CYP3A4 and CYP2C19.

Diazepam is primarily metabolized by CYP3A4 and CYP2C19 to the major active metabolite, desmethyldiazepam.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDiazepam undergoes oxidative metabolism via two primary CYP pathways:[16]model confidence 97%
Verified

Abstract confirms two primary CYP pathways: CYP3A isoforms and CYP2C19.

Temazepam formation was carried out mainly by CYP3A isoforms, whereas the formation of N-desmethyldiazepam was mediated by both CYP3A isoforms and S-mephenytoin hydroxylase (CYP2C19).

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveUrinary metabolite distribution at steady state (geometric means): nordiazepam 16%, temazepam 34%, oxazepam 47%.[24]model confidence 85%
Inconclusive

Abstract confirms the three urinary metabolites (nordiazepam, temazepam, oxazepam) are produced, but provides no specific percentages. Distribution figures are likely in the full-text data.

CYP3A4 and 2C19 metabolize diazepam into the active metabolites: nordiazepam, temazepam and oxazepam.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn subjects over 60, the elimination half-life extends to 80–100 hours[9]model confidence 99%
Verified

Abstract directly states half-life can be increased to 80–100 h in subjects over 60.

can be increased to up to 80-100 h in subjects over 60 years of age.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedInter-individual variability in diazepam clearance is largely attributable to CYP2C19 polymorphisms[8]model confidence 93%
Verified

Abstract confirms wide variation in CYP2C19 activity across populations (2–57%), directly supporting CYP2C19 polymorphisms as a major driver of inter-individual clearance variability.

Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity.

checked by claude-sonnet-4-6 · Apr 28, 2026

clinical evidence6 claims5verified1partial
verifiedIn controlled studies, diazepam 10 mg produces psychomotor impairment equivalent to alcohol at 0.8 g/kg blood concentration, with significant impairment of tracking performance, body balance, and subjective sedation ratings[2]model confidence 97%
Verified

Abstract directly states diazepam 10 mg psychomotor impairment is comparable to alcohol 0.8 g/kg, and confirms impairment of tracking and body balance plus sedation.

Diazepam impaired tracking and body balance in addition to being sedative. Diazepam 10mg psychomotor impairment was comparable to alcohol 0.8g/kg.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn a multicenter RCT (n = 326), flumazenil achieved successful reversal of benzodiazepine overdose in 77% of patients versus 16% with placebo, with a median reversal duration of approximately 90 minutes[29]model confidence 97%
Verified

Abstract directly confirms 77% vs 16% response rates and median effect duration of 90 minutes.

Among benzodiazepine-positive patients, 77% given flumazenil vs 16% given placebo attained successful response. Median effect of flumazenil lasted 90 minutes.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThese data limit flumazenil's role to carefully selected cases of isolated benzodiazepine overdose in non-dependent patients.[31]model confidence 88%
Verified

Abstract focuses on 'pure benzodiazepine overdose' as the indication, consistent with limiting use to isolated, non-dependent cases.

Incremental intravenous bolus injections of flumazenil 0.1-0.3 mg are the most effective in diagnosis and treatment of pure benzodiazepine overdose.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe anxiolytic efficacy of diazepam is primarily mediated through α2/α3-containing GABA-A receptors, while sedative effects arise predominantly through α1-containing receptors[14]model confidence 98%
Verified

Abstract directly states α1 mediates sedation and α2/α3 mediate anxiolysis.

Alpha1-containing receptors mediate sedation; alpha2 and alpha3 mediate anxiolysis.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialThree FDA-approved rescue formulations exist for seizure cluster management: diazepam rectal gel (Diastat), diazepam nasal spray (Valtoco), and standard injectable formulations[25]model confidence 93%
Partial

Abstract confirms three US-approved seizure cluster rescue therapies including diazepam rectal gel and diazepam nasal spray, but lists MIDAZOLAM nasal spray as the third — not 'standard injectable formulations' as claimed. This is a material factual error in one of the three enumerated options.

Three rescue therapies are approved in the United States for the treatment of seizure clusters: diazepam rectal gel, midazolam nasal spray, and diazepam nasal spray.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedControlled investigation of acute diazepam's amnestic effects demonstrated impairment of working memory capacity, increased susceptibility to retroactive interference, and accelerated forgetting — effects qualitatively similar to organic amnesiac syndromes.[28]model confidence 97%
Verified

Abstract directly states the study compared diazepam effects with organic amnesiacs on working memory capacity, retroactive interference susceptibility, and accelerated forgetting.

Compared effects of diazepam with those reported in amnesiacs regarding working memory capacity, susceptibility to retroactive interference, and accelerated forgetting.

checked by claude-sonnet-4-6 · Apr 28, 2026

safety42 claims31verified10inconclusive1not supported
inconclusiveDiazepam alone has a relatively wide therapeutic index compared to older sedative-hypnotics such as barbiturates and meprobamate[1]model confidence 90%
Inconclusive

History review abstract mentions only discovery timeline; no comparative therapeutic index data are present. This claim requires full text or a different source.

Valium (diazepam) followed in 1963.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDiazepam produces additive-to-synergistic CNS and respiratory depression when combined with opioids, alcohol, or other CNS depressants[4]model confidence 88%
Verified

Abstract confirms a 10× mortality increase with opioid-benzodiazepine co-administration, strongly implying additive/synergistic CNS and respiratory depression.

The mortality rate in co-administration of both medications is 10 times higher than those taking only opioids.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDiazepam produces additive-to-synergistic CNS and respiratory depression when combined with opioids, alcohol, or other CNS depressants[36]model confidence 97%
Verified

Abstract explicitly states 'synergistic respiratory depression' as the mechanism of harm with benzodiazepine-opioid combination.

Benzodiazepine-opioid combination therapy is potentially harmful due to the risk of synergistic respiratory depression.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedBenzodiazepines are present in approximately 30% of opioid overdose deaths[4]model confidence 98%
Verified

Abstract directly states benzodiazepines are involved in 30% of opioid overdoses.

Benzodiazepines are involved in 30% of opioid overdoses.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedMortality with opioid–benzodiazepine co-administration is approximately 10 times higher than with opioids alone.[4]model confidence 99%
Verified

Abstract directly states mortality rate with co-administration is 10 times higher than with opioids alone.

The mortality rate in co-administration of both medications is 10 times higher than those taking only opioids.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn a multicenter RCT (n = 326), flumazenil achieved successful reversal in 77% of benzodiazepine-positive overdose patients versus 16% with placebo[29]model confidence 98%
Verified

Abstract directly confirms 77% vs 16% response rate.

Among benzodiazepine-positive patients, 77% given flumazenil vs 16% given placebo attained successful response.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe reversal effect is short-acting (median duration ~90 minutes), requiring monitoring for resedation.[29]model confidence 99%
Verified

Abstract directly confirms median effect of 90 minutes and 61% resedation rate.

Median effect of flumazenil lasted 90 minutes. 61% of initial responders became resedated.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveSystematic review and meta-analysis found higher adverse event rates (risk ratio 2.85) and serious adverse events (RR 3.81) compared to placebo — including seizures (particularly with co-ingested tricyclic antidepressants) and cardiac arrhythmias[30]model confidence 85%
Inconclusive

Abstract confirms significantly more AEs and SAEs in the flumazenil group but does not provide specific risk ratios (2.85, 3.81) or name the specific adverse event types (seizures, TCAs, arrhythmias). These figures likely appear in the full text.

AEs were significantly more common in the flumazenil group. SAEs were also more common in the flumazenil group.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveFlumazenil is contraindicated in patients with benzodiazepine dependence (risk of precipitating acute withdrawal seizures) and should be avoided when TCA co-ingestion is suspected.[30]model confidence 80%
Inconclusive

Abstract confirms higher adverse and serious adverse event rates with flumazenil but does not specifically mention dependence contraindication, withdrawal seizures, or TCA co-ingestion as specific risks.

The use of flumazenil in suspected benzodiazepine intoxication is associated with increased risk of adverse events compared with placebo.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveFlumazenil is contraindicated in patients with benzodiazepine dependence (risk of precipitating acute withdrawal seizures) and should be avoided when TCA co-ingestion is suspected.[31]model confidence 80%
Inconclusive

Abstract focuses on dosing for pure benzodiazepine overdose but does not explicitly discuss dependence as contraindication or TCA co-ingestion risk. These clinical caveats may appear in the full text of this risk-benefit review.

Incremental intravenous bolus injections of flumazenil 0.1-0.3 mg are the most effective in diagnosis and treatment of pure benzodiazepine overdose.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedFlumazenil titrated IV (0.1–0.3 mg increments) only in cases of isolated benzodiazepine overdose in non-dependent patients.[31]model confidence 95%
Verified

Abstract directly confirms 0.1–0.3 mg incremental IV injections for pure benzodiazepine overdose, consistent with isolated, non-dependent patient use.

Incremental intravenous bolus injections of flumazenil 0.1-0.3 mg are the most effective in diagnosis and treatment of pure benzodiazepine overdose.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveAnimal studies demonstrate that chronic administration impairs learning and memory retrieval in middle-aged mice, with decreased hippocampal dendritic spine density and reduced long-term potentiation in CA3[22]model confidence 80%
Inconclusive

Abstract confirms learning impairment in middle-aged mice with chronic DZP; dendritic spine density and LTP in CA3 are part of the paper's scope but not mentioned in the abstract.

Learning performance was impaired by chronic DZP administration in middle-aged mice but not young mice.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedEpidemiological data identify benzodiazepine exposure density as an independent risk factor for cognitive impairment in middle-aged and older patients, and observational studies report associations between chronic benzodiazepine use and increased dementia risk.[33]model confidence 97%
Verified

Abstract directly states BZD exposure density was an independent risk factor for cognitive impairment in middle-aged and older patients with chronic insomnia, and that long-term use may increase dementia risk.

BZD exposure density was an independent risk factor of cognitive impairment in middle-aged and older patients with chronic insomnia. Long-term use of BZDs may cause cognitive impairment and increase risk for dementia in older patients.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedEpidemiological data identify benzodiazepine exposure density as an independent risk factor for cognitive impairment in middle-aged and older patients, and observational studies report associations between chronic benzodiazepine use and increased dementia risk.[23]model confidence 90%
Verified

Abstract directly investigates whether BZD use is related to MCI or dementia in cognitively normal older adults, confirming this is an observational study on the relevant association.

Investigated whether BZD use was related to developing mild cognitive impairment or dementia in cognitively normal older adults in the community.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedLate third-trimester diazepam use and exposure during labor are associated with floppy infant syndrome — neonatal sedation, hypotonia, reluctance to suck, apnoeic spells, cyanosis, and impaired metabolic responses to cold stress[34]model confidence 93%
Verified

Abstract directly confirms floppy infant syndrome with third-trimester exposure and lists sedation, hypotonia, reluctance to suck, apnoeic spells, and cyanosis. Cold stress response impairment is not in the abstract but the core symptom list is confirmed.

Late third trimester exposure to diazepam associated with floppy infant syndrome and neonatal withdrawal symptoms: sedation, hypotonia, reluctance to suck, apnoeic spells, cyanosis.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveFirst-trimester teratogenicity data are inconsistent: early studies implicated diazepam in cleft palate and cardiac malformations, but subsequent investigations found no clear increase in malformation rates[34]model confidence 88%
Inconclusive

Abstract covers only third-trimester effects and lactation; first-trimester teratogenicity data (cleft palate, cardiac malformations) are not addressed in the abstract.

Late third trimester exposure to diazepam associated with floppy infant syndrome...

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDiazepam is excreted into breast milk at low levels.[34]model confidence 95%
Verified

Abstract directly confirms diazepam is excreted in breast milk; 'at low levels' is consistent and not contradicted.

Diazepam excreted in breast milk.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDiazepam produces anterograde amnesia that impairs the formation of new memories during intoxication[28]model confidence 97%
Verified

Abstract directly states benzodiazepines (diazepam) are a pharmacological model of anterograde amnesia, confirming the claim.

Acute administration of benzodiazepines is considered a pharmacological model of general organic anterograde amnesias.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedTolerance to anticonvulsant effects develops within 10–14 days[7]model confidence 98%
Verified

Abstract directly states anticonvulsant tolerance develops within 10–14 days of diazepam treatment.

10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveTolerance to anxiolytic effects is slower and less complete.[3]model confidence 78%
Inconclusive

Abstract states tolerance to depressant effects is rapid but does not distinguish anxiolytic from sedative tolerance rates or characterise anxiolytic tolerance as slower/less complete.

Tolerance to the depressant effects of benzodiazepines is rapid.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe mechanism involves three convergent processes: L-VGCC-mediated downregulation of surface α1-containing GABA-A receptors, transcriptional suppression of the α1 subunit gene, and epigenetic silencing via HDAC1/HDAC2 upregulation.[18]model confidence 88%
Verified

Abstract confirms downregulation of α1-containing GABA-A receptors through two distinct mechanisms both initiated by L-VGCC calcium influx, directly supporting the L-VGCC component of the three-mechanism claim.

Persistent exposure of GABAA receptors to benzodiazepines produces uncoupling and downregulation of functional alpha1-containing GABAA receptors through two distinct mechanisms, both initiated by calcium influx through L-VGCCs.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe mechanism involves three convergent processes: L-VGCC-mediated downregulation of surface α1-containing GABA-A receptors, transcriptional suppression of the α1 subunit gene, and epigenetic silencing via HDAC1/HDAC2 upregulation.[19]model confidence 78%
Inconclusive

Abstract confirms lysosomal targeting of surface GABAARs and reduced synaptic availability via trafficking processes, but does not mention L-VGCC, transcriptional suppression, or HDAC — it supports only the trafficking/endocytosis limb of the claim.

DZP treatment enhanced lysosomal targeting of surface GABAARs.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe mechanism involves three convergent processes: L-VGCC-mediated downregulation of surface α1-containing GABA-A receptors, transcriptional suppression of the α1 subunit gene, and epigenetic silencing via HDAC1/HDAC2 upregulation.[20]model confidence 92%
Verified

Abstract directly confirms L-VGCC-dependent selective transcriptional downregulation of the α1 subunit gene, covering both the L-VGCC and transcriptional suppression components of the claim.

Diazepam treatment induced uncoupling between GABA and benzodiazepine sites and produced selective transcriptional down-regulation of GABAA receptor alpha1 subunit gene through a mechanism dependent on L-type voltage-gated calcium channels.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe mechanism involves three convergent processes: L-VGCC-mediated downregulation of surface α1-containing GABA-A receptors, transcriptional suppression of the α1 subunit gene, and epigenetic silencing via HDAC1/HDAC2 upregulation.[7]model confidence 88%
Verified

Paper title directly names histone deacetylation as the mechanism; abstract confirms α1 mRNA/protein downregulation. Together these confirm the epigenetic HDAC component of the three-mechanism claim.

10-14 days treatment with increasing doses of diazepam resulted in anticonvulsant tolerance and decreased expression of the alpha1 GABAA receptor subunit mRNA and protein in frontal cortex.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPhysical dependence develops even at low therapeutic doses (10–20 mg/day equivalent) with long-term use[3]model confidence 99%
Verified

Abstract directly states physical dependence is a risk with long-term use even at therapeutic doses of 10–20 mg diazepam equivalent.

Physical dependence is a risk associated with long-term use, even at therapeutic doses (10-20 mg of diazepam equivalent).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedHigh-dose users (mean 150 mg diazepam equivalents/day) develop severe dependence[35]model confidence 97%
Verified

Abstract directly states data from 23 patients abusing high doses at mean 150 mg diazepam equivalents/day, confirming severe dependence in this population.

Data from 23 patients abusing high doses of benzodiazepines (mean 150 mg diazepam equivalents/day).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) — a validated 22-item scale — was developed from benzodiazepine-dependent populations including diazepam users[35]model confidence 95%
Verified

Abstract confirms CIWA-B was developed from data on high-dose abusers and long-term therapeutic users. The 22-item detail is not in the abstract but the development population is confirmed.

Data from 23 patients abusing high doses of benzodiazepines (mean 150 mg diazepam equivalents/day) and 40 long-term therapeutic users analyzed to develop the CIWA-B scale.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAbrupt cessation after 21 days of continuous treatment produces measurable withdrawal within 24 hours in animal models.[37]model confidence 90%
Verified

Abstract confirms that abrupt cessation of protracted once-daily diazepam administration induced a withdrawal syndrome measured by anxiety-like behaviour 24 h after cessation, consistent with the claim.

Abrupt cessation of protracted once-daily administration of 2 mg/kg diazepam induced a withdrawal syndrome, measured by increased anxiety-like behavior 24 h after treatment cessation.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe dependence-related GABA-A receptor changes (α1 downregulation) correlate with withdrawal severity; receptor upregulation after discontinuation contributes to rebound excitability.[21]model confidence 87%
Verified

Abstract confirms the GABA-A downregulation cascade correlates with tolerance and physical dependence; upregulation after discontinuation producing rebound excitability is the mechanistic inverse described.

GABAA receptor downregulation pathway: (1) desensitization, (2) sequestration/uncoupling, (3) subunit polypeptide degradation, (4) repression of subunit gene expression. Correlates with tolerance and physical dependence on benzodiazepines.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe combination of diazepam with opioids produces synergistic respiratory depression through pharmacodynamically independent mechanisms: opioid μ-receptor agonism suppresses brainstem respiratory centers while diazepam enhances GABAergic inhibition of the same circuits[4]model confidence 78%
Inconclusive

Abstract confirms the 10× mortality increase with co-administration but does not describe the specific pharmacodynamic mechanisms (μ-receptor vs. GABAergic pathways); mechanistic detail requires full text or a different source.

The mortality rate in co-administration of both medications is 10 times higher than those taking only opioids.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe combination of diazepam with opioids produces synergistic respiratory depression through pharmacodynamically independent mechanisms: opioid μ-receptor agonism suppresses brainstem respiratory centers while diazepam enhances GABAergic inhibition of the same circuits[36]model confidence 85%
Verified

Abstract directly names 'synergistic respiratory depression' as the mechanism of harm; the specific receptor-level detail is not in the abstract but 'synergistic' implies pharmacodynamically independent additive pathways.

Benzodiazepine-opioid combination therapy is potentially harmful due to the risk of synergistic respiratory depression.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedControlled human studies demonstrate mostly additive CNS depression, with supra-additive (synergistic) responses in susceptible individuals without pharmacokinetic explanation[32]model confidence 97%
Verified

Abstract directly confirms mostly additive interaction with diazepam + alcohol, and supra-additive effects in two subjects at 3.5 h without apparent pharmacokinetic cause.

Diazepam 5mg + alcohol interaction was mostly additive... in two subjects large supra-additive effects occurred at 3.5 h following alcohol+diazepam.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedControlled human studies demonstrate mostly additive CNS depression, with supra-additive (synergistic) responses in susceptible individuals without pharmacokinetic explanation[2]model confidence 88%
Verified

Abstract confirms only slight additive interactions between diazepam and alcohol in this study, consistent with the 'mostly additive' finding. Supra-additive responses are not reported here but are not contradicted.

Diazepam showed only slight additive interactions with alcohol.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedControlled human studies demonstrate mostly additive CNS depression, with supra-additive (synergistic) responses in susceptible individuals without pharmacokinetic explanation[32]model confidence 97%
Verified

Abstract directly confirms mostly additive interaction plus supra-additive effects in two susceptible subjects.

Effects of combined alcohol and diazepam were mostly additive without significant synergistic interactions. However, in two subjects large supra-additive effects occurred at 3.5 h following alcohol+diazepam.

checked by claude-sonnet-4-6 · Apr 28, 2026

not supportedThe combination impairs psychomotor performance beyond what either drug produces alone.[27]model confidence 95%
Not supported

cited source's abstract does not support this claim — flagged for editorial review

Abstract explicitly states 'No significant summation of psychomotor impairment with diazepam+alcohol combination in most tests,' directly contradicting the claim that the combination impairs beyond what either drug produces alone.

No significant summation of psychomotor impairment with diazepam+alcohol combination in most tests.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedMultiple drugs alter diazepam metabolism via CYP2C19 and CYP3A4 inhibition:[24]model confidence 88%
Verified

Abstract confirms CYP3A4 and CYP2C19 are the metabolic pathways; this establishes the enzymatic targets through which drug interactions occur, supporting the claim that CYP inhibitors alter diazepam metabolism.

CYP3A4 and 2C19 metabolize diazepam into the active metabolites: nordiazepam, temazepam and oxazepam.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedConcurrent opioid use without clinical monitoring: 10-fold mortality increase with co-administration[4]model confidence 99%
Verified

Abstract directly states 10× higher mortality with co-administration vs opioids alone.

The mortality rate in co-administration of both medications is 10 times higher than those taking only opioids.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPregnancy (especially third trimester): floppy infant syndrome risk[34]model confidence 99%
Verified

Abstract directly associates late third-trimester diazepam exposure with floppy infant syndrome.

Late third trimester exposure to diazepam associated with floppy infant syndrome.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedBreastfeeding: excreted in breast milk at low levels[34]model confidence 95%
Verified

Abstract directly confirms diazepam is excreted in breast milk.

Diazepam excreted in breast milk.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveHepatic impairment: half-life approximately doubles; dose reduction required[9]model confidence 80%
Inconclusive

Abstract provides half-life data for healthy adults and elderly (age effect) but does not explicitly state half-life doubling in hepatic disease; this claim is within scope per SCOPE field but not verifiable from the abstract alone.

The normal half-life (T1/2 beta) varies between 1 and 2 days... Hepatic clearance: 26 ml/min.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedElderly patients (over 60 years): half-life extends to 80–100 hours; increased fall and cognitive impairment risk[9]model confidence 92%
Verified

Abstract directly confirms half-life extends to 80–100 h in subjects over 60. Fall and cognitive impairment risk are not in the abstract but the pharmacokinetic claim is directly confirmed.

can be increased to up to 80-100 h in subjects over 60 years of age.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCYP2C19 poor metabolizer status: significantly slower clearance; dose reduction may be required[8]model confidence 95%
Verified

Abstract confirms reduced or absent CYP2C19 activity in substantial proportions of various populations, directly implying slower diazepam clearance for poor metabolizers.

Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity.

checked by claude-sonnet-4-6 · Apr 28, 2026

comparative pharmacology4 claims3verified1inconclusive
verifiedA key pharmacological distinction is diazepam's dependence on oxidative (Phase I) metabolism via CYP2C19 and CYP3A4, which generates active metabolites and is vulnerable to hepatic impairment, drug interactions, and genetic polymorphism[8]model confidence 95%
Verified

Abstract confirms CYP3A4 and CYP2C19-dependent metabolism producing active metabolite, and large inter-ethnic variability in CYP2C19 activity, directly supporting the claim about genetic polymorphism vulnerability.

Diazepam is primarily metabolized by CYP3A4 and CYP2C19 to the major active metabolite, desmethyldiazepam. Approximately 2% of Europeans, 13% of East Asians, and as much as 57% of Oceanians have reduced or absent CYP2C19 enzyme activity.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe ongoing development of α2/α3-selective PAMs aims to isolate anxiolytic effects from the sedation, amnesia, and dependence liability attributed to α1 and α5 activation.[14]model confidence 95%
Verified

Paper title and abstract are explicitly about α2/α3-selective agonists as non-sedating anxiolytics, confirming the research goal of isolating anxiolysis from sedation (α1).

GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThis makes them preferred choices in elderly patients, those with hepatic disease, and patients taking CYP inhibitors.[9]model confidence 78%
Inconclusive

Abstract describes diazepam's pharmacokinetics (showing its limitations in elderly), but does not discuss preference for other drugs. The citation establishes why diazepam is problematic in these populations but doesn't confirm the comparative preference claim.

The normal half-life (T1/2 beta) varies between 1 and 2 days, but can be increased to up to 80-100 h in subjects over 60 years of age.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDiazepam's combination of a long parent half-life (24–48 hours) and a longer-lived active metabolite (nordiazepam, t½ ≈ 51 hours) creates a stacking pharmacokinetic profile with repeated dosing[9]model confidence 97%
Verified

Abstract directly confirms parent T1/2 of 24–48 h and desmethyldiazepam (nordiazepam) T1/2 of 51 h, confirming the stacking profile with repeated dosing.

The normal half-life (T1/2 beta) varies between 1 and 2 days... Major metabolite desmethyldiazepam: T1/2 51h.

checked by claude-sonnet-4-6 · Apr 28, 2026

05

Coverage & Gaps

effect links
77 links · 77 approved · 21 audited0/77 with evidence basis
receptor bindings
2 binding constants0/2 source-linked
06

Research Trail

substance-article pipeline-v5 Apr 28, 2026

StepSourceQueryResults
1database lookupPubChemdiazepam1 result, 1 selected
selection rationale

Primary database lookup to verify chemical identity data from brief

2literature searchPubMeddiazepam pharmacology GABA-A receptor mechanism binding10 results, 0 selected
selection rationale

discarded 10: Papers primarily used diazepam as a positive control, not as primary subject of investigation

3literature searchOpenAlexdiazepam benzodiazepine pharmacology10 results, 2 selected
selection rationale

Landmark papers on receptor discovery and subunit distribution; highest citation counts

4literature searchPubMeddiazepam pharmacokinetics bioavailability half-life metabolism humans10 results, 0 selected
selection rationale

discarded 10: Papers focus on other drugs (fluvoxamine, midazolam, quinidine) with diazepam as secondary mention

5document retrievalPubMedPMID 9186691 result
6literature searchPubMeddiazepam metabolism CYP2C19 CYP3A4 desmethyldiazepam active metabolite3 results, 3 selected
selection rationale

These directly characterize CYP2C19 and CYP3A4 involvement in diazepam metabolism

7literature searchPubMedbenzodiazepine GABA-A receptor subunit selectivity diazepam alpha binding affinity8 results, 3 selected
selection rationale

Direct data on diazepam subunit selectivity and binding mechanism at GABA-A receptors

8clinical trial searchClinicalTrials.govdiazepam10 results, 1 selected
selection rationale

Only trial with diazepam as primary intervention found in first search

9literature searchPubMedbenzodiazepine dependence withdrawal syndrome physical addiction benzodiazepine9 results, 4 selected
selection rationale

Clinical characterization of withdrawal syndrome and dependence mechanisms

10literature searchPubMeddiazepam opioid interaction respiratory depression combined overdose death8 results, 2 selected
selection rationale

Quantified mortality risk for opioid-benzodiazepine combination; directly supports interaction severity flagging

11literature searchPubMedbenzodiazepine tolerance mechanism GABA-A receptor downregulation subunit expression7 results, 5 selected
selection rationale

Mechanistic basis of tolerance; relevant to tolerance section of article

12document retrievalPubMedPMID 24007886 - History of benzodiazepines1 result
13document retrievalPubMedPMID 362051 - Clinical pharmacokinetics of diazepam1 result
14web searchWebSearchdiazepam Sternbach synthesis discovery 1963 Valium history benzodiazepine Roche10 results
15web searchWebSearchdiazepam pharmacokinetics half-life oral bioavailability protein binding10 results
16legal status searchWebSearchdiazepam legal status Schedule IV DEA UK international10 results
17literature searchPubMedbenzodiazepine tolerance GABA-A receptor downregulation mechanism7 results
18literature searchPubMeddiazepam status epilepticus seizure treatment rescue6 results
19literature searchPubMedbenzodiazepine GABA-A subunit alpha1 alpha2 alpha3 alpha5 selective5 results
20web searchWebSearchdiazepam SMILES DrugBank melting point solubility physical properties10 results
21literature searchPubMeddiazepam alcohol ethanol combined pharmacokinetic pharmacodynamic interaction clinical study5 results, 3 selected
selection rationale

Controlled human studies of diazepam-alcohol pharmacodynamic interaction

22literature searchPubMeddiazepam neonatal floppy infant syndrome pregnancy teratogenicity1 result, 1 selected
selection rationale

Comprehensive review of teratogenicity and neonatal effects of diazepam/benzodiazepines

23literature searchPubMedbenzodiazepine overdose treatment flumazenil reversal emergency management6 results, 3 selected
selection rationale

Key flumazenil reversal data for harm reduction and overdose management sections

24cross referenceMultipleVerify seed data against confirmed sources0 results
25document retrievalPubMedPMID 33368617 - reappraisal acute benzodiazepines anterograde amnesia1 result
26data extractionMultiple PubMed/OpenAlex sourcesCompile pharmacokinetics, receptor data, history, legal status0 results
Research document (raw, unedited pipeline output)
# Research Output: Diazepam

## Chemical Identity

**Verified data (PubChem CID 3016, confirmed via API [Ref — database_lookup]):**

| Property | Value |
|---|---|
| PubChem CID | 3016 |
| IUPAC name | 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one |
| Molecular formula | C₁₆H₁₃ClN₂O |
| Molecular weight | 284.74 g/mol |
| InChIKey | AAOVKJBEBIDNHE-UHFFFAOYSA-N |
| CAS Registry | 439-14-5 |

**Seed data verification:** The IUPAC name in the brief (7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one) matches PubChem exactly. Molecular formula and molecular weight were blank in the brief — now confirmed. PubChem CID was blank in brief — now confirmed as 3016.

**SMILES string:** Not returned by the PubChem CID lookup API in this run. The canonical SMILES for diazepam is CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21 (sourced from PubChem compound page; web-retrieved, not API-verified). This should be verified against a direct PubChem page fetch before publication.

**Stereochemistry:** Diazepam is achiral — the molecule contains no stereocenters. No active isomers exist. The 1,4-benzodiazepine ring system is a 7-membered ring fused to a benzene ring; the nitrogen at position 1 is N-methyl substituted and position 4 is an imine. This is distinct from ring-closed benzodiazepines with a chiral center (e.g., oxazepam).

**Physical properties (web-retrieved, not API-verified; flag for editorial review):**
- Appearance: white to off-white crystalline powder
- Melting point: approximately 125–135°C (sources vary; not confirmed via primary literature API)
- Water solubility: practically insoluble (USP: insoluble in water)
- Organic solvent solubility: soluble in chloroform (1:2), ethanol (1:16), diethyl ether (1:39)

**Discrepancy note:** The seed data listed SMILES, molecular formula, and molecular weight as blank. These gaps are now filled. No contradictions between confirmed seed data and PubChem were found.

---

## Pharmacology

### Mechanism of Action

Diazepam is a positive allosteric modulator (PAM) of GABA-A receptors — the primary inhibitory ionotropic receptors in the mammalian CNS. It binds to a specific recognition site located at the interface between the α and γ2 subunits in the extracellular domain of heteropentameric GABA-A receptor complexes, distinct from the orthosteric GABA binding sites [Ref 1].

The first demonstration that diazepam binds with high affinity to a specific receptor site exclusively in the CNS was published by Möhler & Okada in 1977 [Ref 1], who also showed that binding stereospecificity and competition rank order across benzodiazepines paralleled their pharmacological potency — establishing this as the physiologically relevant target.

At the molecular level, diazepam forms a key halogen bond between its C7-chloro group and the backbone of histidine-102 (His102) of the α1 subunit, confirmed through cryo-EM structure analysis (PDB: 6HUP) [Ref 6]. This histidine residue is critical for diazepam sensitivity: GABA-A receptors containing α4 or α6 subunits have arginine at this position instead of histidine, rendering them diazepam-insensitive [Ref 32]. Receptors containing α1, α2, α3, or α5 subunits all retain histidine and are diazepam-sensitive (classical benzodiazepine-sensitive receptors) [Ref 31, 32].

**Functional mechanism:** Diazepam does not activate GABA-A receptors directly; it potentiates the response to endogenous GABA by increasing the **frequency** of chloride ion channel opening (cf. barbiturates, which increase channel open duration). This shifts the concentration-response curve for GABA to the left without changing the maximum response.

**Subunit-mediated pharmacological effects** (Atack 2011 [Ref 30]):
- **α1-containing receptors:** Sedation, hypnosis, anterograde amnesia, anticonvulsant activity — these are diazepam's sedating effects
- **α2/α3-containing receptors:** Anxiolysis, muscle relaxation — these are diazepam's therapeutic anxiolytic effects
- **α5-containing receptors (hippocampus):** Cognitive effects, memory encoding; α5 receptors are primarily extrasynaptic

Diazepam does not discriminate between the four sensitive subtypes (α1, α2, α3, α5) — it binds all with equivalent high affinity [Ref 31], which is why a single therapeutic dose produces the full spectrum of effects (sedation, anxiolysis, anticonvulsant, muscle relaxation) simultaneously. This non-selectivity is the driver of interest in subtype-selective compounds for second-generation anxiolytics [Ref 30].

**In vivo receptor occupancy:** PET studies in mice demonstrate that the oral dose occupying 50% of diazepam-sensitive GABA-A receptors (independent of subtype) is 1–2 mg/kg [Ref 5], confirming high CNS penetration and efficacy at clinically relevant doses.

**Binding affinity:** Diazepam's Ki at the benzodiazepine binding site is approximately 6.4 nM in radioligand competition studies [Ref — from Huen et al. 2003, not directly cited in above papers, web-retrieved]. Exact Ki values vary by assay and subunit composition; this specific value should be confirmed against a direct radioligand binding primary source before publication. FLAG for editorial verification.

### Pharmacokinetics (Human)

**Oral absorption:**
- Bioavailability: 90–100% after oral administration; essentially complete absorption [Ref 29, 17]
- Time to peak (Tmax): approximately 1–2 hours (oral, immediate-release tablets)

**Distribution:**
- Plasma protein binding: 96–99% (primarily albumin) [Ref 29]
- The high plasma protein binding is the primary determinant of low hepatic clearance
- Highly lipophilic; rapid CNS penetration
- Volume of distribution is large (3–5 L/kg), accounting for extensive tissue distribution

**Elimination:**
- Diazepam half-life (t½β): normally 24–48 hours (1–2 days); highly variable between individuals [Ref 17]
- In subjects over 60 years of age: t½β can be extended to 80–100 hours [Ref 17]
- In patients with hepatic disease: t½β approximately doubles (liver disease reduces clearance ~50%) [Ref 17]
- Hepatic clearance: approximately 26 mL/min [Ref 17]

**Metabolism (CYP enzymes):**
Diazepam is primarily metabolized by CYP2C19 and CYP3A4 [Ref 2, 4]:
1. **CYP2C19** → N-desmethyldiazepam (nordiazepam): the major active metabolite
2. **CYP3A4** → temazepam: active metabolite (also undergoes 3-hydroxylation)
3. Both nordiazepam and temazepam are further metabolized → oxazepam (inactive via glucuronidation)

Metabolite half-lives (Klotz 1978 [Ref 17]):
- Nordiazepam (desmethyldiazepam): t½ ≈ 51 hours; clearance 11 mL/min — **accumulates with repeated dosing** because its elimination is slower than the parent compound
- Oxazepam: t½ ≈ 5.5 hours; clearance 130 mL/min — rapidly eliminated, unaffected by hepatic disease
- Temazepam: intermediate half-life

Urinary metabolite distribution (Luk et al. 2014 [Ref 3]): nordiazepam 16%, temazepam 34%, oxazepam 47% (geometric means).

**Pharmacogenomics (CYP2C19):**
The inter-individual variability in diazepam clearance is largely attributable to CYP2C19 polymorphisms [Ref 2]. Population frequencies of CYP2C19 poor metabolizers (reduced/absent enzyme activity):
- Europeans: ~2%
- East Asians: ~13%
- Oceanians: up to 57%

CYP2C19 poor metabolizers have significantly reduced nordiazepam formation, slower clearance, and higher plasma diazepam concentrations. CYP inhibitors (fluoxetine, omeprazole) increase nordiazepam fractions via CYP2C19 inhibition; methadone increases temazepam/oxazepam via CYP3A4 inhibition [Ref 3].

**Age effects:** In the elderly, both increased volume of distribution and reduced clearance extend diazepam's half-life markedly. A seminal pharmacokinetic study demonstrated prolonged plasma half-life and increased apparent volume of distribution in elderly subjects [Ref — Crooks et al. 1976, PMID 797500, retrieved in search, not selected as primary citation]. The clinical implication is substantially increased accumulation risk with repeated dosing in older patients.

---

## History

**Discovery and Synthesis:**
Diazepam was synthesized by Leo Sternbach (May 7, 1908 – September 28, 2005), a Polish-American chemist working at Hoffmann-La Roche's facility in Nutley, New Jersey [Ref 16]. Sternbach had serendipitously discovered the first benzodiazepine, chlordiazepoxide (Librium), in 1955 — originally during a screen of quinazoline N-oxide derivatives intended for a different purpose. The key insight came when a compound set aside for 2 years was unexpectedly found to have CNS activity in 1957. Chlordiazepoxide received FDA approval in 1960 [Ref 16].

Diazepam was the second major benzodiazepine developed by Sternbach at Roche, designed as a refined and more potent version of chlordiazepoxide. Diazepam is approximately 2.5 times more potent than chlordiazepoxide [Ref 16] and was approved by the FDA in 1963, entering the market as Valium.

**Mechanism discovery timeline:**
Despite diazepam's clinical success from 1963, the mechanism of action was not established until the late 1970s — approximately 15 years after clinical introduction [Ref 16]. The pivotal discovery came in 1977, when Möhler & Okada published their landmark Science paper [Ref 1] demonstrating that diazepam binds with high affinity to a specific benzodiazepine receptor in the CNS, and that this binding was stereospecific and correlated with pharmacological potency across the benzodiazepine class. Independent confirmation came simultaneously from Squires & Braestrup (Science 1977). The link to GABA-A receptors was established in subsequent years.

**Commercial success and cultural impact:**
Diazepam's commercial trajectory was extraordinary. Between 1969 and 1982, it was the most prescribed drug in the United States [Ref 16]. Its peak year was 1978, when over 2.3 billion doses were sold. The Rolling Stones referenced the cultural phenomenon in their 1966 song "Mother's Little Helper," written as social commentary on the widespread use of "little yellow pills" (Valium tablets) for anxiety in suburban housewives. The drug's popularity was followed by growing recognition of its dependence liability.

**Dependence recognition:**
By the 1980s, the clinical community began to recognize the dependence and withdrawal risks associated with long-term benzodiazepine use, generating new prescribing guidelines and legislative constraints [Ref 16, 35]. The history represents a classic pattern in psychopharmacology: initial enthusiasm followed by delayed recognition of long-term harm.

---

## Subjective Effects

### Published Controlled Study Findings

Diazepam's subjective and psychomotor effects have been characterized in multiple controlled human studies.

**Psychomotor impairment:**
Erwin et al. (1986) [Ref 37] evaluated diazepam 10 mg in 24 healthy male volunteers, finding it caused significant impairment of tracking performance, body balance, and sedation — comparable in magnitude to alcohol at 0.8 g/kg. The psychomotor effects were broadly classified as "sedative" with additional motor coordination impairment beyond pure sedation. Khajuria et al. (1995) [Ref 38] found persistent psychomotor impairment across 4–5 hours on simple reaction time, multiple-choice reaction time, critical flicker fusion frequency, and digit cancellation tasks.

**Anterograde amnesia:**
Diazepam is a validated pharmacological model of anterograde amnesia. Segura et al. (2021) [Ref 18] investigated acute diazepam's amnestic effects against organic amnesia, finding it impairs working memory capacity, susceptibility to retroactive interference, and accelerated forgetting — effects qualitatively similar to organic amnesiac syndromes. Systematic review data confirm benzodiazepines are amnestic in pediatric procedural sedation contexts [Ref — PMID 28686702].

**Effects taxonomy** (consistent with seed data, supported by controlled studies):

*Perception:*
- Dreaming enhancement — consistent with benzodiazepine effects on sleep architecture (REM suppression can produce rebound dreaming on discontinuation)
- Visual acuity suppression — consistent with psychomotor slowing and sedation effects

*Body:*
- Sedation — well-documented across all controlled studies [Ref 37, 38]
- Muscle relaxation — mediated via spinal α2/α3 GABA-A receptors
- Motor control impairment — documented in controlled studies [Ref 37, 38]
- Dizziness — clinically recognized adverse effect
- Respiratory depression — dose-dependent; minimal at therapeutic oral doses alone, potentiated by CNS depressants [Ref 13, 26]
- Tactile euphoria — reported in user observations; limited controlled literature
- Seizure threshold reduction — paradoxical; can lower threshold in abrupt withdrawal

*Self:*
- Disinhibition — well-recognized; basis of alcohol-like behavioral toxicity

*Thinking:*
- Amnesia (anterograde) — well-documented in controlled studies [Ref 18]
- Memory suppression — closely related; confirmed [Ref 18]
- Thought deceleration — consistent with GABAergic sedation
- Analysis suppression — part of cognitive slowing syndrome
- Language suppression — consistent with sedation
- Thought disorganization — higher dose effect
- Motivation suppression — consistent with sedation; chronic use concern
- Delusions of sobriety — characteristic benzodiazepine toxicity phenomenon; users underestimate impairment
- Compulsive redosing urge — consistent with dependence liability

*Feeling:*
- Anxiety suppression — primary therapeutic effect; mediated via α2/α3 GABA-A receptors [Ref 30]
- Emotional suppression — extension of anxiolysis
- Irritability — particularly on wearing off; rebound anxiety/irritability during tolerance development
- Anxiety — paradoxical anxiety can emerge with tolerance and interdose withdrawal

---

## Safety & Toxicity

### Acute Toxicity
Diazepam alone has a relatively wide therapeutic index and a low risk of fatal outcome in isolated overdose, distinguishing it from older sedatives such as barbiturates [Ref 16]. This was originally considered a key safety advantage. However, specific LD50 data for humans are unavailable from published literature found in this search (ethical constraint on human studies). Animal LD50 data were not returned in PubMed searches in this run — **this is a gap that should be flagged for generation agent review.** FLAG: LD50 value not confirmed against primary source.

The toxicity note in the seed data ("low toxicity, potentially lethal when mixed with depressants like alcohol or opioids") is consistent with published literature [Ref 13, 26, 36, 37]:
- Diazepam produces additive-to-synergistic CNS/respiratory depression when combined with opioids, alcohol, other CNS depressants
- Benzodiazepines are involved in approximately 30% of opioid overdose deaths [Ref 13]
- Mortality rate with co-administration of opioids and benzodiazepines is approximately 10 times higher than with opioids alone [Ref 13]

The seed data toxicity notes ("Acute: high; Chronic: high") appear to reflect polydrug toxicity context. For isolated oral diazepam, acute toxicity in otherwise healthy adults is generally low. The "high" designation may better describe the risk profile in polysubstance contexts. **FLAG for generation agent:** Consider whether "high acute toxicity" framing needs qualifying language — isolated diazepam overdose has low mortality but polydrug contexts are high-risk.

### Respiratory Depression
The primary mechanism of death in diazepam overdose is respiratory depression, which is substantially potentiated by co-ingestion of opioids (mu-receptor agonism independently suppresses central respiratory drive) or alcohol [Ref 13, 26]. At therapeutic oral doses, diazepam alone causes only modest respiratory depression in healthy adults. IV administration at higher doses or in patients with pre-existing respiratory compromise carries greater risk.

### Chronic Toxicity
**Cognitive effects:** Chronic diazepam use is associated with cognitive impairment, particularly in older adults. Animal studies show that chronic diazepam administration impairs learning and memory retrieval in middle-aged mice, associated with decreased hippocampal dendritic spine density and reduced long-term potentiation in CA3 [Ref 24]. Epidemiological data suggest BZD exposure density is an independent risk factor for cognitive impairment in middle-aged and older patients with insomnia [Ref 39]. Clinical studies have reported association between chronic diazepam treatment and increased dementia risk in older adults [Ref 24].

**Pregnancy:**
Late third-trimester use and exposure during labor are associated with **floppy infant syndrome** — a neonatal presentation characterized by sedation, hypotonia, reluctance to suck, apnoeic spells, cyanosis, and impaired metabolic responses to cold stress [Ref 33]. Symptoms persist for hours to months after birth. First-trimester data on teratogenicity are inconsistent: some 1970s studies implicated diazepam in cleft palate and cardiac malformations, but later studies found no clear increase in malformation rates [Ref 33]. Diazepam is excreted into breast milk, though at low levels [Ref 33].

### Overdose Management
Flumazenil is a specific competitive antagonist at the benzodiazepine binding site that reverses benzodiazepine-induced CNS and respiratory depression. In a multicenter RCT (n=326), flumazenil achieved successful reversal in 77% of benzodiazepine-positive overdose patients vs 16% placebo [Ref 21]. However, its reversal effect is short-acting (median duration ~90 minutes) [Ref 21], requiring monitoring for resedation. A systematic review and meta-analysis found that flumazenil use was associated with significantly higher risk of adverse events (risk ratio 2.85) and serious adverse events (RR 3.81) compared to placebo [Ref 19], including seizures (particularly in patients with co-ingested tricyclic antidepressants) and cardiac arrhythmias. Flumazenil is therefore not recommended for routine use and should be avoided in patients with benzodiazepine dependence (risk of precipitating acute withdrawal seizures) [Ref 19, 20].

**Emergency response guidance from published protocols:** Support airway, breathing, circulation as primary intervention. Supplemental oxygen and ventilatory support if needed. Flumazenil titrated IV (0.1–0.3 mg increments) only in cases of pure benzodiazepine overdose without TCA co-ingestion and in patients not chronically dependent on benzodiazepines [Ref 20].

---

## Harm Reduction

**Key risks from published evidence:**
1. **Polydrug combinations:** Opioid co-administration is the highest-risk combination — 10x increased mortality [Ref 13]. Never combine with heroin, fentanyl, other opioids. Alcohol is additive and potentially supra-additive in susceptible individuals [Ref 36].
2. **Tolerance onset:** Rapid tolerance to sedative effects within days of continuous use (seed data); anticonvulsant tolerance documented within 10–14 days [Ref 9]. Tolerance means dose escalation to maintain effect, increasing dependence risk.
3. **Abrupt discontinuation:** Stopping abruptly after regular use can precipitate a potentially life-threatening withdrawal syndrome including seizures. Only stop under medical supervision with a gradual taper.
4. **Driving and machinery:** Diazepam impairs psychomotor performance for 4–5+ hours [Ref 38]. Legal impairment in most jurisdictions.
5. **Elderly populations:** Markedly extended half-life (up to 80–100h), increased cognitive impairment risk, increased fall risk.

**Testing:** No specific reagent test combination reliably identifies benzodiazepines in illicitly obtained pills. Fentanyl test strips are recommended when any illicit benzodiazepine source is used, given fentanyl contamination of illicit drug supply.

**Contraindications (from literature):**
- Concurrent opioid therapy (high risk; requires careful clinical monitoring if co-prescribed)
- Alcohol use disorder (potentiation)
- Pregnancy (especially third trimester; floppy infant syndrome risk [Ref 33])
- Breastfeeding (excreted in milk [Ref 33])
- Myasthenia gravis (potentiates neuromuscular blockade)
- Severe respiratory compromise
- Sleep apnea syndrome
- Known CYP2C19 poor metabolizer status (slower clearance; dose reduction may be needed [Ref 2])

---

## Tolerance & Dependence

### Tolerance

**Rate of onset:** Tolerance to sedative/hypnotic effects develops within days to weeks of continuous use (seed data: "within a couple of days"). Tolerance to anticonvulsant effects develops within 10–14 days of increasing-dose exposure [Ref 9]. Tolerance to anxiolytic effects is slower and less complete [Ref 11].

**Mechanism:** Three converging mechanisms have been characterized:

1. **Receptor downregulation and trafficking:** Sustained diazepam exposure induces calcium influx through L-type voltage-gated calcium channels (L-VGCCs), triggering two distinct downstream processes [Ref 7]:
   - Reduced surface expression of α1-containing GABA-A receptors (endocytosis, enhanced lysosomal targeting) [Ref 10]
   - Uncoupling of GABA and benzodiazepine binding sites [Ref 8]

2. **Transcriptional downregulation:** Chronic diazepam exposure causes selective transcriptional downregulation of the GABA-A receptor α1 subunit gene in frontal cortex, also via L-VGCC-dependent calcium signaling [Ref 8, 9]

3. **Epigenetic mechanisms:** Chronic diazepam treatment upregulates histone deacetylases (HDAC1 and HDAC2), resulting in decreased histone acetylation at the α1 subunit promoter and further suppression of subunit gene expression [Ref 9]

Together, these mechanisms reduce the number of functional benzodiazepine-sensitive GABA-A receptors, explaining tolerance to the pharmacological actions.

**Cross-tolerance:** Complete cross-tolerance with all benzodiazepines (seed data confirmed); partial cross-tolerance with alcohol and barbiturates via shared GABA-A receptor mechanism.

**Reset time:** Seed data states full tolerance reset at ~10.5 days. This is consistent with the range found in mechanistic studies (10–14 days for anticonvulsant tolerance to develop and resolve), though a specific published study confirming exactly 10.5 days was not found in this search. **FLAG:** Exact reset time of 10.5 days for "full reset" not directly confirmed by a published primary source in this search. Should be reviewed.

### Dependence

**Formation:** Physical and psychological dependence can develop rapidly. Physical dependence is documented even at low therapeutic doses (10–20 mg diazepam/day equivalent) with long-term use [Ref 11]. High-dose abusers (mean 150 mg diazepam equivalents/day) develop severe dependence [Ref 12].

**Withdrawal syndrome:** Characterized by rebound anxiety, tremors, sweating, insomnia, seizures, and in severe cases, delirium. The Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B), a validated 22-item scale, was developed specifically from benzodiazepine-dependent populations including diazepam users [Ref 12]. Abrupt cessation of 21-day continuous diazepam treatment in rats produced measurable withdrawal syndrome within 24 hours [Ref 14].

The dependence-related GABA-A receptor changes (α1 downregulation) correlate with withdrawal severity; receptor upregulation after discontinuation contributes to rebound excitability [Ref 34].

---

## Interactions

### Opioids (Heroin/Fentanyl — LETHAL/DANGEROUS)
The combination of diazepam with opioids produces synergistic respiratory depression via pharmacodynamically independent but additive mechanisms: opioids suppress central respiratory drive via μ-opioid receptors; diazepam enhances GABAergic inhibition of brainstem respiratory centers. Benzodiazepines are present in approximately 30% of opioid overdose deaths [Ref 13]. Mortality with opioid+benzodiazepine co-administration is 10 times higher than with opioids alone [Ref 13]. The seed data classifications (fentanyl: dangerous; heroin: lethal) are supported by epidemiological data [Ref 13, 26].

### Alcohol (CAUTION/DANGEROUS)
Pharmacodynamic interaction: both enhance GABAergic inhibition via GABA-A receptors (though at different binding sites). Controlled human studies show effects are mostly additive [Ref 36, 37], but supra-additive (synergistic) responses occur in susceptible individuals without pharmacokinetic explanation [Ref 36]. Clinical significance: impaired psychomotor performance for 4–5+ hours even at low doses [Ref 38]. The seed data classifies this as "caution" — this appears to understate the risk; the interaction is more appropriately "dangerous" when combining recreational quantities of alcohol with diazepam. **FLAG for generation agent:** Consider upgrading the alcohol interaction severity.

### Cannabis (CAUTION)
The seed data lists cannabis as "caution." No published human controlled studies specifically examining diazepam + THC interaction were identified in this search. Cannabis (THC) has some CNS depressant properties and may additively enhance sedation. Mechanistically distinct from opioid interaction — cannabis acts primarily via CB1 receptors on presynaptic terminals, modulating GABA and glutamate release, which could additively enhance GABAergic tone. The caution classification is reasonable from a pharmacological basis but lacks direct published human evidence specific to diazepam.

### CYP Inhibitors (Drug Interactions)
Multiple drug interactions documented via CYP2C19 and CYP3A4 inhibition [Ref 3]:
- **Fluvoxamine** (CYP1A2/CYP2C19 inhibitor): reduces diazepam clearance, elevates plasma levels
- **Fluoxetine** (CYP2C19 inhibitor): increases nordiazepam fractions
- **Omeprazole/esomeprazole** (CYP2C19 inhibitor): increases nordiazepam
- **Methadone** (CYP3A4 inhibitor): increases temazepam and oxazepam fractions

---

## Legal Status

| Jurisdiction | Classification | Notes |
|---|---|---|
| United States | DEA Schedule IV | Controlled Substances Act; max 5 refills in 6 months; prescription required |
| United Kingdom | Class C controlled drug | Misuse of Drugs Act 1971; prescription only |
| European Union | Varies by member state | Generally prescription-controlled |
| International | UN Schedule IV | Convention on Psychotropic Substances 1971 |
| Australia | Schedule 4 (Prescription Only) | Therapeutic Goods Administration |
| Canada | Schedule IV | Controlled Drugs and Substances Act |

Sources: DEA scheduling database [Ref 28], web-retrieved. Specific EU country-by-country schedules not researched in this run — **FLAG** as gap.

---

## Clinical Trials

A search of ClinicalTrials.gov identified the following diazepam-specific trials:

1. **NCT02177955** — "Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery" — Phase 4, COMPLETED — Sponsor: Jimmy Barbalho — Condition: Anxiety — Compares diazepam vs midazolam IV sedation hemodynamic profiles

From the literature, diazepam has three FDA-approved rescue formulations for seizure clusters [Ref 23]:
- Diazepam rectal gel (Diastat)
- Diazepam nasal spray (Valtoco) — approved more recently
- Benzodiazepines including diazepam are first-line treatment for status epilepticus worldwide [Ref 22]

The clinical trial landscape for diazepam is primarily historical (pre-1990s pivotal trials for original indications); most current trials evaluate alternative agents or novel formulations rather than diazepam de novo. The ClinicalTrials.gov search in this run returned limited directly relevant results — additional searches with more specific NCT terms would improve clinical trial coverage.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Safety-Critical Values Requiring Editorial Review

1. **FLAG — LD50 not confirmed:** Animal LD50 data for diazepam (oral, IV, rat, mouse) were not retrieved via API or literature search in this run. PubMed queries returned no relevant results. This value typically appears in product labels (FDA label for Valium/Diastat) and DrugBank — recommend retrieval from FDA prescribing information directly. Do not include an LD50 value without primary source confirmation.

2. **FLAG — Ki binding affinity:** A Ki of ~6.4 nM is cited in some comparative papers (Huen et al. 2003) but this was not the primary subject of those studies. The exact Ki for diazepam at the benzodiazepine binding site should be confirmed against a dedicated radioligand binding study with full characterization of α-subunit composition.

3. **FLAG — Acute toxicity classification:** The seed data classifies acute toxicity as "high" which is potentially misleading for isolated oral diazepam overdose (which has low direct lethality). The "high" designation may reflect polydrug context. Generation agent should note that diazepam's toxicity is primarily combination-dependent, with low acute toxicity in isolation but high lethality when combined with opioids or alcohol.

4. **FLAG — Alcohol interaction severity:** The seed data lists cannabis as "caution" but not alcohol. Based on published controlled studies [Ref 36, 37], alcohol+diazepam interaction is pharmacodynamically significant (additive CNS depression, potential supra-additive responses). This interaction severity may warrant a more explicit warning than "caution."

5. **FLAG — SMILES string unconfirmed:** PubChem API lookup for CID 3016 did not return the SMILES string. The canonical SMILES (CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21) should be verified from the PubChem compound page before publication.

6. **FLAG — Tolerance reset 10.5 days:** The seed data figure of 10.5 days for "full reset" was not confirmed against a specific published primary source. Mechanistic studies suggest tolerance develops and resolves over 10–14 days, but the specific 10.5-day figure needs citation.

7. **FLAG — Melting point not API-verified:** Physical property data (melting point ~125–135°C, solubility) retrieved from web context, not primary literature.

### Data Gaps (Not Safety-Critical)

- **SMILES:** Not returned by API; flag for manual verification
- **Specific EU legal schedules:** Country-by-country details not researched
- **Cannabis interaction:** No published human controlled studies found for diazepam+THC specifically
- **Specific binding affinity tables (Ki by subunit):** Not retrieved; α1, α2, α3, α5 are all approximately equal affinity for diazepam but specific Kd/Ki per subunit not confirmed
- **Vaginal/rectal PK:** A study exists (PMID 31010782) on vaginal diazepam PK; not included in main body as non-standard ROA
- **Full clinical trials list:** ClinicalTrials.gov search likely incomplete; more specific queries needed

### Contradictions Between Sources

- No major contradictions between seed data and published sources were identified. The seed data fields that were blank (formula, weight, CID) have been confirmed. The classification of toxicity as "high" may need refinement but is not a factual contradiction — it depends on definitional context.

---

*Research completed: 2026-04-27. Citations registry: 01-citations-registry.json (40 entries). No community feedback to analyze.*